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CHAPTER I 

GENERAL INTRODUCTION. 
From 1980 we have treated patients with idiopathic membranous 
glomerulonephritis with high-dose alternate-day prednisone 
according to the protocol of the Collaborative Study of the 
Adult Idiopathic Nephrotic Syndrome [1]. While treating these 
patients we observed a typical fluctuating pattern of proteinu-
ria, due to an increased protein excretion on prednisone days 
and a decreased proteinuria on non-prednisone days [2]. To ex-
plain this peculiar phenomenon we have systematically studied 
the acute effects of corticosteroid treatment on proteinuria in 
patients with idiopathic membranous glomerulonephritis. These 
studies, described in chapters VI-VIII, form the main part of 
this thesis. In chapter II we review facts on idiopathic mem-
branous glomerulonephritis, its natural history and treatment 
modalities. Factors related to the measurements of proteinuria 
and renal function in patients with renal diseases are descri-
bed in chapters III-V. Finally, we address the course of the 
disease and possible benefits of treatment with corticosteroids 
and other immunosuppressive drugs in our patients in chapters 
IX and X. 
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CHAPTER II 
MEMBRANOUS GLOMERULONEPHRITIS: A REVIEW 

INTRODUCTION 
Membranous glomerulonephritis is a chronic glomerular disease 
with a well-defined histopathological picture, characterized by 
the presence of subepithelial immune deposits on electron 
microscopy [1]. Under light microscopy the glomeruli show 
thickening of the capillary wall in the absence of cellular 
proliferation. Silver stains show densely staining projections 
into the basement membrane known as "spikes". Presumably these 
spikes represent normal basement membrane extending between the 
abovementioned deposits. In immunofluorescence microscopy 
granular deposits containing IgG and C3 are found in the 
capillary walls. 
Although the incidence of membranous glomerulonephritis is 
rather low [approximately 10 new cases/million/year] [2], it is 
the most common cause of the nephrotic syndrome in adults, 
being the underlying glomerular disorder in about a quarter of 
nephrotic patients [1]. Membranous glomerulonephritis may be 
associated with a number of underlying diseases or toxins 
[table I], but in most cases [70 - 85%] no underlying cause can 
Table I. Causes of secondary membranous glomerulonephritis 
Malignancies: carcinoma (lung, breast, colon) 
lymphoma 
Infections: hepatitis В 
syphilis 
malaria 
filariasis 
Drugs: gold 
penicillamine 
Captopril 
NSAID 
Auto-immune diseases: SLE 
thyreoiditis 
Miscellaneous: sarcoidosis 
diabetes mellitus 
Adapted from ref. 1, 14, and 48 
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be identified [idiopathic membranous glomerulonephritis]. 
Familial occurrence of idiopathic membranous glomerulonephritis 
has been described in rare cases [1,3]. In Caucasians idiopa-
thic membranous glomerulonephritis has been associated with the 
histocompatibility antigens DR3, B18, and B8 [4-6], whereas 
from Japan a predominant association with DR2 was reported [7]. 
NATURAL HISTORY OF IDIOPATHIC MEMBRANOUS GLOMERULONEPHRITIS. 
Idiopathic membranous glomerulonephritis occurs most commonly 
in adults between 30 and 50 years of age [8] . Males are more 
frequently affected than females in a ratio of 2:1. The short-
term outcome [<five years] of membranous glomerulonephritis has 
been extensively reported on [9-16]. However, it is difficult 
to compare the results because most of the older studies suffer 
from the handicap that not only patients with secondary forms 
of membranous glomerulonephritis were included, but also trea-
ted as well as untreated patients. Furthermore the studies are 
quite heterogeneous regarding the proportions of female 
patients, the number of patients presenting with asymptomatic 
proteinuria, and the prevalence of other prognostic factors. In 
the abovementioned studies complete remission of proteinuria 
occurs in about 16% to 29% of patients, whereas about 40-60% of 
patients show evidence of progressive renal insufficiency, up 
to 38% reaching end stage renal disease [ESRD] within five 
years after onset of the disease. In table II an overview of 
recent studies on the outcome of idiopathic membranous glomeru-
lonephritis in untreated patients is presented. It is evident 
that the results of these studies are quite variable, the 
percentage of patients entering a complete or partial remission 
of proteinuria ranging from about 20% to 65%. Likewise the 
percentage of patients, developing renal insufficiency varies 
from nearly 20% to over 50%. Also, the rate of progression is 
quite variable. However, overall the disease follows a rather 
indolent course, only 5-23% of patients reaching ESRD within 
five years after presentation. From these studies it is evident 
that time of follow-up is rather important, the frequency of 
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Table II. Outcane of idiopathic manbranous glomerulonephritis in untreated patients 
Pat. Sex Age NS 
Screat at 
presentation Follow-up CR 
(No.) (W/F) (years) (%) (μιηοΐ/ΐ) (% abn.) (years) (%) 
Outcane 
Doubling ESRD 
of Screat within 
IR RFD after two five years 
(%) (%) years (%) (%) Ref. 
116 60/56 38 
(5-80) 
76 ND 4.5 
(0.2-21.5) 
23.5 14.5 19 12 17 
64 47/17 45 
(20-70) 
81 110 33 7 
(2-15) 
ND ND 52 12.5 23 18 
38 20/18 35 
(16-65) 
100 90 
(±18) (0.3-4.3) 
10.5 7.9 >29 36 15.8 19 
77 44/33 45 
(16-83) 
73 103 
(±9) 
23 4.0 
(2-10) 
35 30 25 <10 5.2 20 
39 29/10 42 
(16-74) 
100 93 
(±25) 
5.0 
(2-11) 
18 >49 13 8-12 21 
89 56/33 50 
(11-81) 
83 116 
(±50) 
6.1 
(0.2-14) 
-57- 33 12 16 22 
37 31/6 42 
(17-72) 
93 130 
(50-660) 
16 5.3 
(2.5-9.3) 
22 47 ND ND 23 
Abbreviations: М=пв1е; F^female; NS=nephrotic syndrome; Screat=serum creatinine; abn=abnonnal; Ofcranplete 
remission of proteinuria; Hí=partial remission; RFD=renal function deterioration. ND=no data 
Table III. 
Patients 
(No.) 
, long-term outcome 
Sex Age 
(tyF) (years) 
in idiopathic membranous glomerulonephritis 
NS SCreat at presentation Follow up 
(%) (μιηοΐ/ΐ) (% abnormal) (yfars) 
CR 
(%) 
Outcome 
PR 
(%) 
RFD 
(%) Ref. 
35 18/17 
49 37/12 
104 64/40 
36 74 
(7-69) 
ND 45.7 
47 100 108±27 
(13-70) 
40 68.3 ND 
(15-81) 
20 
14 
(10-20) 
9.5 
(2-26) 
11.5 
(1.0-24) 
29 
14.3 
40 
23 
40 
30 
43 
45 
30 
24 
25 
26 
Abbreviations: see table II. 
patients going into complete remission increasing with time. In 
Cattran's study the percentage of patients with a complete 
remission increased from 15% at one year to 35% after four 
years [20]. In the study of Noel a complete remission was 
reached after on average 5.1 years of follow-up [17], whereas 
Ponticelli did not observe a single complete remission in 
untreated patients within two years after their entry into the 
study [21] . It is also important to note that many authors 
indicate that, if patients develop renal insufficiency, this 
occurs with few exceptions within two to three years after 
presentation [17,18], and that prognosis in patients with 
normal renal function at five years after presentation is good. 
Because of this indolent course of idiopathic membranous 
glomerulonephritis and in view of the fact that the number of 
patients with complete or partial remission of proteinuria in-
creases with time it would be important to know the long-term 
outcome [>10 years] of idiopathic membranous glomerulonephri-
tis. Only few studies have thusfar been reported however [table 
III], and in only one, patients were untreated [25]. These 
studies confirm the idea that idiopathic membranous glomerulo-
nephritis has a variable course, in the long run about 50% of 
patients reaching complete or partial remission and about 50% 
progressing to renal insufficiency. Persistent nephrotic 
syndrome after 10 years of follow-up is present in only 4-9% of 
patients [24,27]. The evolution to end-stage renal disease is 
rather slow, about 25-30% of patients being dialysis-dependent 
after a follow-up of 10 years. In the Japanese study a more 
favourable prognosis is given, a complete or partial remission 
of proteinuria being reported in about 70% of patients, only 
four out of 104 patients reaching ESRD after a mean follow-up 
of 11.5 years [26]. 
PROGNOSTIC FACTORS 
From these and other studies a number of clinical and histolo-
gical factors have emerged which determine the risk of develo-
ping renal insufficiency. An overview of these risks factors 
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Table IV. Prognostic factors in membranous glomerulonephritis 
Sex (18,19,21,28,29) 
Age (18,30,31) 
Race (26) 
Renal function at presentation (17,18) 
Proteinuria (17,18,22,29) 
Selectivity index (19) 
Histological stage of glomerular lesions (25,29) 
Tubulo-interstitial changes (17,21,24) 
HLA-DR3, HLA-B18, BfFl (5) 
Number in brackets refer to the references 
is given in table IV. We will address the importance of these 
factors briefly. 
Sex. In general, membranous glomerulonephritis has a favourable 
course in women. Hopper and colleagues found a complete 
remission in 16 of 33 women [48%] as compared to 5 of 37 men 
[14%][28]. Likewise, in another study, a complete or partial 
remission occurred in 6 of 6 women as compared to 17 of 26 male 
patients [21]. Deterioration of renal function is less likely 
in women. Evidence of renal function deterioration was seen in 
35% of women and 58% of men [19], and ESRD was reached in 10% 
of women after a mean follow-up of 88 months and in 39% of men 
after a mean follow-up of 66 months [29]. 
Age. Prognosis in children is rather good. In a study of 50 
children, who where followed for one to 10 years [mean 4 
years], 26 reached a complete remission and only five children 
progressed to renal failure [30]. When comparing the outcome in 
patients with onset of membranous glomerulonephritis before or 
after the age of 15 years Cameron reached a similar conclusion 
[31]. Remission of proteinuria was less likely in adults [16% 
vs 49%] and ESRD was more frequent [19% vs 4%]. Some authors 
feel that a somewhat better prognosis is also observed in 
adults under 30 years of age [18]. 
Race. Japanese patients apparently have a better prognosis, a 
complete or partial remission being reported in 70% of pa-
20 
tients, only four out of 104 patients reaching ESRD after a 
mean follow-up of 11.5 years [26]. 
Renal function at presentation. In patients who present with 
renal insufficiency, renal function almost invariably shows a 
progressive decline. In the study of Davison, 70% of patients 
with a serum creatinine over 120 μιηοΐ/ΐ at onset showed 
progression of renal failure as compared to 24% of patients 
with a serum creatinine below 100 jmol/l [18]. ESRD developed 
in three of seven patients with renal insufficiency as 
compared to eight of 109 patients without renal insufficiency 
[17]. 
Proteinuria. Patients with a nephrotic syndrome have a worse 
prognosis than patients with asymptomatic proteinuria. Evidence 
of progressive renal disease is found in 23% to 58% of nephro­
tic patients as compared to 7% to 25% of patients with asympto­
matic proteinuria [17,18]. Donadío and colleagues calculated 
that after 10 years 5%, 18%, and 60% of patients with proteinu-
ria of 0-3.4 g/24 h, 3.5-10 g/24 h, and >10 g/24 h respective-
ly, had died or had reached ESRD [22]. Since the level of 
proteinuria determines serum albumin concentration it is not 
surprising that sarum albumin concentration correlates with the 
prognosis, 10 year survival approaching 76% in patients with 
albumin >15 g/1 and 56% in patients with a serum albumin below 
15 g/1 [29]. 
Selectivity index. Glomerular proteinuria can be divided into a 
selective or a non-selective pattern based on a comparison of 
the clearance of albumin (or transferrin) with the clearance of 
larger molecular weight proteins (IgG). Based on the idea that 
proteinuria is simply the result of an increased diameter of 
the pores in the glomerular capillary wall, it was assumed that 
the selectivity index (defined as the clearance ratio of IgG: 
albumin (or transferrin) would reflect glomerular damage. 
Patients with a selectivity index less than 0.10 are defined as 
having highly selective proteinuria, and are considered to have 
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only a modest increase in glomerular permeability. In patients 
with membranous glomerulonephritis, a selectivity index below 
0.20 is associated with a better prognosis. Coggins et al 
report a decrease of GFR of 10% per year in 33% of patients 
with selectivity index below 0.2 and in 60% of patients with a 
selectivity index above 0.2 [19]. 
Histological stage. Four pathologic stages have been described 
[1]. A stage I lesion includes small scattered subepithelial 
deposits associated with spike-like irregularities of the 
epithelial surface of the basement membrane. In stage II 
lesions, the deposits are more numerous, larger, and have a 
more uniform distribution throughout the glomerular tuft, and 
the epithelial spikes are prominent. In stage III the deposits 
become completely encircled by lateral extensions of the GBM 
spikes and are thus incorporated in the membrane. Finally, 
stage IV shows a definite rarefaction of the former deposits, 
together with an extremely variable thickening of the GBM. 
Although not confirmed in all studies some authors reported a 
better prognosis in stage I patients, survival being 85% in 
stage I patients as compared to 55% in stage III patients [29]. 
Zuchelli et al. reported a lower incidence of chronic renal 
failure in stage I patients (stage I: 0/12, stage II: 16/49, 
stage III-IV: 14/21)[25]. 
Tubulo-interstitial damage. Although the presence of tubulo-
interstitial changes is associated with a poorer prognosis 
[17,21,24], quantitative data are scarce. Ponticelli et al 
described a relative risk of 3.4 [21]. 
HLA-DR linkage. A subgroup of patients with idiopathic membra-
nous glomerulonephritis possesses the rare allotype of the 
complement component Bf, BfFl, in association with DR3 and B18. 
These patients apparently have a worse prognosis [5] . None of 
the patients reached a sustained remission of proteinuria, and 
three quarter developed renal insufficiency. 
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TREATMENT OF IDIOPATHIC MEMBRANOUS GLOMERULONEPHRITIS. 
Corticosteroids and to a lesser extent other immunosuppressive 
drugs have been used in the treatment of membranous glomerulo-
nephritis. Most studies were uncontrolled and have yielded 
equivocal results [9,10,15,32-35]. Furthermore, uncontrolled 
studies can hardly ever give definitive answers since the 
natural history of membranous glomerulonephritis is quite 
variable and dependent on many factors as discussed in the 
previous section. Only a few controlled studies are available 
for review [table V]. Older studies did not show any benefit of 
steroids [36], azathioprine [37,38], or cyclophosphamide [39]. 
However, since only a small number of patients, followed for a 
rather short period, were included, these studies do not permit 
to exclude any treatment-related benefits. Promising results 
were reported by a French group of investigators who treated 
patients with chlorambucil for 12 months. After a follow-up of 
two years, 13 of 16 chlorambucil-treated patients reached a 
complete or partial remission of proteinuria as compared to 
three of 14 placebo treated patients [40]. However, firm 
conclusions cannot be drawn from this study. First, no data on 
renal function and on deterioration of renal function were 
given. Second, since in untreated patients the percentage of 
patients reaching a remission increases with time, one cannot 
exclude that the difference in this respect between untreated 
and treated patients would eventually have disappeared. Final-
ly, we are left with three large, fully documented controlled 
trials [19-21]. The first study came from the U.S. and was 
reported in 1979 [19]. Patients with idiopathic membranous glo-
merulonephritis and proteinuria of more than 3. 5g/24h/1.73 m2 
were treated with 125-150 mg prednisone on alternate days for 
eight weeks. Follow-up averaged 23 months [range 4-52 months]. 
Although during follow-up complete and partial remissions 
occurred more frequently in treated patients [22/34 vs 11/38; 
p<0.01], at the time of the latest observation this difference 
was less striking: in the treated group four patients were in 
complete remission and eight in partial remission as compared 
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to four and three patients respectively in the placebo group. 
The main effect of treatment concerned the risk of progressive 
renal failure. Eleven of 38 placebo-treated patients experien­
ced a doubling of serum creatinine during follow-up as compared 
to only two of 34 prednisone-treated patients. Although the 
methodology of this study seemed sound, some criticisms should 
be mentioned. Follow-up was rather short and the number of 
complete remissions was similar in both groups. Furthermore, 
the prognosis of the placebo group was exceptionally poor, 
rapid deterioration of renal function occurring in about 30% of 
patients. More recently the efficacy of prednisone treatment 
was addressed in a Canadian study [20]. In this study 81 
patients were treated with 45 mg/m2 prednisone on alternate 
days for six months, 77 untreated patients serving as controls. 
After a mean follow-up of 48 months no differences with respect 
to the occurrence of remissions of proteinuria or to the course 
of renal function could be demonstrated. Although this study 
appears to provide a strong case against any beneficial effects 
of prednisone treatment in idiopathic membranous glomerulone­
phritis, some important points need to be clarified. First, the 
treated [P] and control group differed with respect to several 
prognostic factors, e.g. serum creatinine [P: 120±10 μιηοΐ/ΐ; 
control: 103±9 дтоі/і; p<0.05], proteinuria [P: 6.9+0.8 g/24h; 
control: 5.2±0.9 g/24h; p<0.05], and percentage of female 
patients [P: 25%; control: 44%]. Furthermore, one quarter of 
patients did not have a nephrotic syndrome, and the prognosis 
of the control group was extremely good, 19 of 77 patients 
reaching a complete remission of proteinuria within three 
years, and only a minority of patients showing evidence of 
deteriorating renal function [25 % of patients had a more than 
25% rise of serum creatinine at five years, and only 6% had 
reached ESRD at that time]. The last confounding factor may be 
the interval between the onset of disease and the start of 
treatment. Median known duration of disease at that time was 16 
months in the Canadian study and six months in the U.S. study. 
Taken together this might suggest that institution of treatment 
at an early stage of the disease is more effective. The most 
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Table V. Controlled trials in membranous glomarulonephritis 
Ref. Treatment 
36 
37 
38 
Prednisone 
Control 
Aza/Pred 
Control 
Azathioprine 
Control 
12 
17 
5 
9 
5 
4 
Deterioration 
Patient РоПоьг-ир Proteinuria of renal 
(No.) (years) CR FR f u n c t i o n 
2 no exact data; overall no 
significant differences 
0.5 no exact data; overall no 
significant differences 
39 Cyclophosphamide 11 
Control 11 
40 
19 
20 
21 
Chlorambucil 
Control 
Prednisone 
Control 
Prednisone 
Control 
Chl./Pred. 
Control 
16 
14 
34 
38 
81 
77 
42 
39 
0 
1 
0 
0 
9 
2 
4 
4 
16 
19 
16 
2 
ND 
ND 
4 
2 
4 
1 
8 
3 
24 
19 
12 
7 
2 
3 
stable 
stable 
ND 
ND 
2 
11 
24 
21 
4 
19 
Abbreviations: Pred-prednisone; Aza=azathioprine; chl=chlorambucil; 
<3t=ccrplete remission; Ht=partial remission; ND=no data 
r e c e n t s t u d y came from I t a l y [ 2 1 ] . The i n v e s t i g a t o r s used 
c h l o r a m b u c i l and s t e r o i d s i n a l t e r n a t i n g monthly c o u r s e s f o r 
s i x months. P a t i e n t s were fol lowed f o r an a v e r a g e of f i v e 
y e a r s . T r e a t e d p a t i e n t s e x p e r i e n c e d s i g n i f i c a n t l y more comple te 
and p a r t i a l r e m i s s i o n s of p r o t e i n u r i a [34/41 v s 1 3 / 3 9 ] , which 
were s u s t a i n e d i n most p a t i e n t s . S u b s t a n t i a l d e t e r i o r a t i o n of 
r e n a l f u n c t i o n o c c u r r e d i n only one of t h e t r e a t e d p a t i e n t s , 
whereas 13 of 39 u n t r e a t e d p a t i e n t s showed a d o u b l i n g of serum 
c r e a t i n i n e d u r i n g f o l l o w - u p . The r e s u l t s of t h i s s t u d y a r e very 
p r o m i s i n g , b u t a w a i t f u r t h e r c o n f i r m a t i o n . 
Because of t h e s h o r t - t e r m a d v e r s e e f f e c t s and t h e p o t e n t i a l 
l o n g - t e r m h a z a r d s of p r e d n i s o n e and o t h e r immunosuppress ive 
d r u g s , i t would be i m p o r t a n t t o l i m i t t h i s t r e a t m e n t t o 
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Table VI. Summary of uncontrolled therapeutic trials in patients with membranous 
glomerulonephritis and renal insufficiency1. 
Proteinuria Renal function 
Patients Sex Screat Therapy Follow-up CR PR IM S ESRD Ref. 
(No) (M/F) (μιηοΐ/ΐ) (months) 
8 
15 
10 
7/1 
7/0 
13/2 
7/2 
7/2 
6/4 
194 
(122-312) 
300 
(180-480) 
410 
(160-750) 
222 
(130-300) 
266 
(180-400) 
297 
(185-563) 
Chi/Ρ 
Chl/P 
Ρ 
С/Ρ 
Ρ 
Aza/P 
18 
11 
32 
33 
98 
33 
41 
42 
43 
44 
45 
46 
^Only patients with deteriorating renal function are included. 
Abbreviations: Screat=serumcreatinine, CR=complete remission, PR=partial remission, 
IM=improved, S=stabilised, ESRD=end stage renal disease, Chl=chlorambucil, P=pred-
nisone, C=cyclophosphamide, Aza=azathioprine. 
patients with progressive disease. To our knowledge thusfar no 
controlled trials have been conducted in patients with evidence 
of deteriorating renal function. Recently the results of 
several uncontrolled studies have been reported [41-46]. A 
summary of these studies is given in Table VI. Excellent 
results have been obtained by Mathieson et al, who treated 
eight patients with deteriorating renal function with chloram-
bucil and prednisone using exactly the same regime as Ponticel-
li including the three initial pulses of one gram of methyl-
prednisolone. In all patients proteinuria decreased, one 
patient reaching a complete and three a partial remission. 
Renal function improved in six, and stabilised in one. Although 
in their original article follow-up was rather short averaging 
11 months, the improvement proved to be sustained after a mean 
follow-up of 18 months [47]. From Table VI it is evident that 
beneficial effects in patients with membranous glomerulonephri-
tis and deteriorating renal function have also been reported 
for long-term treatment with cyclophosphamide, azathioprine, 
and/or high dose prednisone. Overall, of 58 patients treated 11 
reached a complete remission and 17 a partial remission of 
proteinuria. More importantly, in nearly three quarter of 
patients renal function improved or stabilized. 
These results indicate that patients with membranous glomerulo-
nephritis and deteriorating renal function may respond to 
several different immunosuppressive regimens. If the results of 
the study of Mathieson et al. are confirmed in further trials 
it would allow us to limit immunosuppressive therapy to 
patients with progressive disease. Treatment could then be 
withheld from patients in whom the disease follows an indolent 
course without progression to renal failure so that they will 
not be exposed to the short-term adverse effects and the 
potential long-term hazards of immunosuppressive drugs. 
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ABSTRACT 
We studied the influence of urinary flow rate on urinary pro-
tein excretion rate in nine patients with renal disease and 
proteinuria of over 1.5 g/24h. Our results demonstrate that 
urinary protein excretion is fairly constant and, at urinary 
flow rates higher than 1.5 ml/min, independent of diuresis. At 
lower urinary flow rates protein excretion is diminished, which 
may result from increased tubular reabsorption of proteins. In 
measuring protein excretion rates, urinary flow rate should be 
accounted for. 
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INTRODUCTION 
Proteinuria is an important marker of renal disease. Correct 
quantitation of urinary protein excretion is important in the 
follow-up of patients, in interpreting therapeutic gains and in 
analysing investigational results. In most cases protein excre-
tion is measured in 24 hour urine samples, but the values will 
vary according to differences in posture, exercise and diet. To 
circumvent this variability, especially when clinical inves-
tigations call for precise measurements, protein excretion rate 
is often measured using urine samples collected over a short 
period of time, the patient being supine during the investiga-
tion. However, urinary flow rate is seldom accounted for. 
There is no consensus regarding the influence of urinary flow 
rate on the excretion of proteins [1]. The results of the few 
studies on this subject are conflicting [2-6]. Furthermore, all 
studies have been performed in normal or diabetic subjects with 
normal or almost normal protein excretion rates. Therefore, we 
have studied the influence of urinary flow rate on protein 
excretion in patients with renal disease and frank proteinuria. 
Our results show that flow rate may influence protein excretion 
at flow rates under 1.0 ml/min, whereas there is no such in-
fluence at flow rates higher than 1.5 ml/min. 
PATIENTS AND METHODS 
We studied nine patients, with a mean age of 42 years (range 
18-69 years) and a mean endogenous creatinine clearance of 84 
ml/min (range 16-125 ml/min). All had proteinuria of over 1.5 
g/24 h. The clinical data are given in table I. 
In each patient a number of consecutive urine samples (mean 8; 
range 4-15) were collected during short intervals of 40-120 min 
either by spontaneous voiding (in eight patients) or an in-
dwelling bladder catheter (patient no.l). Patients were supine 
during the investigation, except during voiding, when they were 
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Table I. Clinical data 
Patient 
no. Sex 
1 M 
2 F 
3 F 
Age 
24 
18 
50 
Diagnosis 
MGN 
FGS/RT 
FGS 
ECC 
(ml/min) 
75 
89 
16 
Medication 
Prednisone 
Prednisone, 
Ciclosporine 
Atenolol, 
Nifedipine, 
Bumetanide 
M 
M 
55 
34 
ML 115 
RT rejection 80 
Acenocoumarol 
6 
7 
8 
9 
M 
F 
F 
F 
57 
49 
22 
69 
MGN 
FGS 
MGN 
MGN 
80 
125 
117 
56 
Prednisone, 
Azathioprine, 
Atenolol, 
Apresoline 
Atenolol 
-
-
Atenolol, 
Chlorthalidone, 
Captopril 
Abbrevations: ECC=Endogenous creatinine clearance; M=Male; 
F=Female; MGN=Membranous glomerulonephritis; FGS=Focal glome-
rular sclerosis;RT=Renal transplantation; ML=Minimal lesions 
glomerulonephritis. 
in an upright or sitting position to ensure complete emptying 
of the bladder. Fluid intake was moderate in order to avoid 
negative effects of excessive hydration or rapid fluctuations 
of urinary flow rate. Salt intake was not controlled. During 
the day of the investigation protein rich meals were not al-
lowed, because of their known influence on glomerular filtra-
tion rate [7]. 
Urine collection periods were exactly timed, urine volume was 
measured, and concentrations of creatinine and protein were 
measured in all urine samples. In patient 1, glomerular filtra-
tion rate was measured simultaneously using Inutest (Polyfruc-
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tosan, Laevosan Gesellschaft, Linz, Austria) as a marker for 
glomerular filtration. Creatinine, protein, and inulin were 
measured using standard colorimetrie methods. 
Spearman's rank correlation coefficients were computed and used 
for statistical analysis. 
RESULTS 
The influence of urinary flow rate on protein excretion rate is 
shown in figures 1 and 2. In three patients (2,3, and 5) flow 
rates above 1.2 ml/min were not achieved. Two of these patients 
had severe proteinuria ( maximum protein excretion rate > 8 
mg/min ). In three patients (4,6, and 7), in whom both low and 
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high flow rates were achieved, the plots of urinary flow rate 
versus urinary protein excretion rate could be resolved in two 
linear parts by visual fit. The results show that protein 
excretion remains fairly constant at flow rates higher than 
1.0-1.5 ml/min. At lower urinary flow rates protein excretion 
is reduced. Similar observations were made for creatinine 
excretion. Figure 1 shows that these changes in urinary protein 
and creatinine excretion in patient 1 were not accompanied by a 
change in inulin clearance, suggesting that glomerular filtra­
tion rate remained constant. 
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solid lines. Broken lines represent a non-significant correla­
tion. 
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DISCUSSION 
Our study demonstrates that at least in patients with overt 
proteinuria urinary protein excretion is fairly constant and 
independent of diuresis at urinary flow rates above 1.5 ml/min. 
At lower urinary flow rates, a possible relation between pro-
tein excretion and urinary flow rate seems to exist. 
To our knowledge, the influence of urinary flow on urinary 
protein excretion rate has only been studied in normal in-
dividuals or diabetic patients with a protein excretion rate in 
the normal range [2-6]. In three studies a correlation of 
urinary flow with urinary protein excretion rate was demonstra-
ted [2,3,6]. However, firm conclusions cannot be drawn from 
these studies. A possible influence of posture was not ac-
counted for in one study [2]. In the two other studies, urinary 
flow was increased by excessive water loading [3,6], which 
causes a short-lived enhancement of protein excretion ascribed 
to an increase of glomerular filtration rate [4]. Lastly, rapid 
changes in urinary flow rate were accepted in all studies, 
which could have biased the results in view of the dead space 
of the tubulo-pelvi-ureteral system. In rat studies, an in-
fluence of tubul'ar flow rate on the excretion of horseradish 
peroxidase (HRP) was found [8]. Injection of HRP, however, 
caused a considerable decline of GFR and an increase of vas-
cular permeability. Therefore, these results are also difficult 
to interpret. 
That proteinuria is independent of diuresis can easily be 
explained since proteins are reabsorbed in the proximal tubule 
[9], whereas changes in urine flow are predominantly modulated 
in the distal and collecting tubules. We found only an in-
fluence of urinary flow rate on proteinuria at flow rates below 
1.0-1.5 ml/min. As indicated by the inulin clearance in patient 
1, it is unlikely that changes in glomerular filtration rate 
are responsible for this effect. Although it is difficult to 
draw firm conclusions from observations in only one patient, 
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this conclusion is strengthened by the fact that in mammals 
variations in urinary flow rate rarely reflect variations in 
renal blood flow, or glomerular filtration rate, unless urinary 
flow is below 0.35 ml/min [10,11]. Indeed, in man and dogs no 
correlation of glomerular filtration rate with urinary flow 
rate was found at flow rates above 0.6 ml/min [12,13]. The 
decrease of urinary protein excretion at low urinary flow rates 
might result from an increased tubular reabsorption of pro-
teins. In such a case, one must assume that at flow rates 
between 0.5-1.5 ml/min changes in proximal tubular fluid reab-
sorption must occur, probably caused by small changes in ex-
tracellular volume, which can directly influence proximal 
tubular fluid reabsorption at constant filtration rates [14]. 
It remains difficult to exclude, however, that the decreased 
protein excretion and its association with a decreased urinary 
flow rate is an artefact, caused by incomplete emptying of the 
bladder, or the sequestration of urinary protein in the urinary 
dead space. 
Our findings that creatinine excretion is flow dependent agree 
with those of others [15]. Whether this effect of urinary flow 
rate on creatinine excretion is an artefact as mentioned above, 
or can be explained by flow dependent tubular secretion, or as 
the result of enhanced creatinine reabsorption in the bladder 
at low flow rates [16], cannot be determined from our data. 
Despite these uncertainties our findings have practical im-
plications. Our study demonstrates that at least in patients 
with renal disease and proteinuria, the protein excretion rate 
is fairly constant at urinary flow rates above 1.5 ml/min. At 
very low flow rates, proteinuria is underestimated. Therefore, 
when studying these patients urinary flow rate should be ac-
counted for. 
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Renal Clearance of Pancreatic and Salivary Amylase Relative to Creatinine Clearance in 
Patients with Renal Disease and Protemuna 
J. F. M. Wetads, J. С M HathentcheM,1 M HeMris,1 A. J HoHsma, and R. A. P. Koene 
To study the charge-selective properties ot the glomerular 
filter in renal disease, we measured the fractional clearance 
relative to creatinine clearance (ECC), of the amylase isoen­
zymes pancreatic amylase and salivary amylase, which have 
identical size but different charge In 63 healthy subjects the 
mean (and SD) fractional excretion of pancreatic amylase 
4 0 7 % (1 24%), was fourfold that of salivary amylase 1 0 2 % 
(0 54%) For 29 patients with renal disease and proteinuria, 
the mean fractional excretion of pancreatic amylase was 
significantly lower, 3 3 1 % (1 9 4 % ) , and that of salivary amy­
lase significantly higher, 2 0 6 % (1 4 1 % ) , than in controls In 
these patients, fractional excretions of both these isoen­
zymes were negatively correlated with urinary excretion of 
¿-microglobulin and ECC Evidently, differences in clear-
ances of pancreatic and salivary amylase are a consequence 
of differences in charge-related glomerular filtration The 
relative increase of salivary amylase clearance in patients 
with renal disease and proteinuria Is most probably caused 
by a loss ol the charge-selective properties of the glomerular 
basement membrane 
Human serum amylase (1,4-a-D-glucanglucanohydrolase, 
EC 3 2 1 1) consists of two major isomers, pancreatic amy-
lase (P-amylase) and salivary amylase (S-amylase), which 
have identical size (2 9 nm), but different charge, S-amylase 
(isoelectric point 5 9-6 4) being more anionic than P-amy-
lase (isoelectric point 7 0) (J, 2) The unnary excretion of 
amylase is governed by glomerular filtration and tubular 
reabsorption (3, 4) It has gradually become evident that 
transport of macromolecules through the glomerular filter is 
determined not only by the size of the molecule, but also to 
an important degree by its charge (5-7) The negatively 
charged glomerular basement membrane impairs filtration 
of anionic proteins such as albumin Because of the differ-
ences in charge of P- and S-amylase, one might expect 
important differences in renal clearance of these isoen-
zymes However, differences in renal processing of amylase 
isoenzymes have received little attention Therefore, we 
measured the renal clearance of amylase isoenzymes in 
patients with renal disease and proteinuria and compared 
the results with our values for healthy volunteers Our 
results show a preferential increase of clearance of S-
amylase over P-amylase in patients with renal disease and 
proteinuria, pointing to a defect in the charge-selective 
characteristics of the glomerular basement membrane 
Patients and Methods 
Patients Amylase clearances were measured in 63 
healthy controls (group I) and in 29 patients with renal 
disease and proteinuria (group II) 
Group I comprised 34 men and 29 women with a mean (± 
SD) age of 39 ± 18 years (range 18-85 y) All volunteers had 
normal renal function (mean serum creatinine 78 ± 10 
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μπιοΙ/L), and no evidence of any underlying disease 
Group И comprised 19 men and 10 women, with a mean 
age of 43 ± 16 years (range 17-67 y), a mean serum 
creatinine of 165 ± 107 fimoVL, a mean creatinine clearance 
of 78 ± 42 mL'min, and mean proteinuria of 7 0 ± 3 7 g/24 h 
(range 0 5-14 5 g/24 h) The underlying renal disease was 
glomerular in nature in all but one of the patients membra­
nous glomerulonephritis (n = 11), fooal glomerulosclerosis 
(n - 6), minimal change glomerulonephritis (n = 4), IgA 
nephropathy (n = 4), mesangiocapillary glomerulonephntu 
(n = 1), amyloidosis (n = 1), Alport hereditary nephntte (n 
= 1), and pyelonephritis (n = 1) Informed consent was 
obtained from all volunteers and patiente 
Clearance protocol Results of pilot experiments showed 
that both amylase isoenzymes could be accurately measured 
only if the unnary pH was between 6 8 and 7 2 Therefore 
the subjects were administered 4 g of sodium bicarbonate 
orally on the evening before the study and another 2 g In the 
morning at 2 h before unne collection All subjects were 
asked to dnnk 500 mL of tap water, to promote diuresis 
Thereafter a 2-h unne specimen was collected in 10 mL of 
phosphate buffer (1 0 mol/L, pH 7 0) Blood was sampled in 
the middle of this 2-h interval 
Determinations We measured catalytic activity concen­
trations of total amylase and its isoenzymes, using the "Blue 
Starch" method (Phadebas, Pharmacia, Uppsala, Sweden), 
at 37 °C To all unne samples we added 1 mg of bovine 
serum albumin per milliliter All measurements were done 
in unfrozen samples within 48 h after collection We deter­
mined P- and S-amylase by the method of O'Donnell et al, 
using an S-amylase inhibitor (β) Creatinine m serum and 
unne was determined by the J affé technique (9) Proteinuria 
was measured by the biuret method In 22 of the patients we 
concurrently measured the unnary excretion of ft micro-
globulin by radioimmunoassay (ftM-RLA, Pharmacia, up-
per limit in healthy subjects 0 15 μg/mln) 
Calculations Clearances were calculated by the usual 
formula 
clearance, = (U, · V/P.) 
where U, is the concentration of substance χ in unne, V is 
the unne flow rate, and P, is the concentration of substance 
χ in the plasma 
Clearance of creatinine was used as marker of glomerular 
filtration rate Fractional excretions of amylase and its 
isoenzymes were calculated as clearance of amylase divided 
by creatinine clearance, and expressed as percentages 
Statistical analysis We used the Wilcoxon test for un­
paired observations Correlation was calculated according to 
Spearman A P-value of <0 05 was considered significant 
Unless otherwise mentioned, all values are given as means 
± SD In cases of nonparametnc distribution, median values 
are also given 
Resulte 
Table 1 gives values for total amylase and its isoenzymes 
m serum and for fractional excretions Two of the healthy 
volunteers showed no S-amylase in serum, and in a further 
11 no S-amylase was found in unne Therefore, fractional 
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Table 1. Results of Amylase Measurements In Control 
Subjects and Patients with Renal Disease 
Control »ubloct· Patlont* 
(η = S3) (η = 29) 
Serum 
Tolal amylase. U/L 201 ± 49 
p-amylase. U/L 98 + 34 
S-amylase, U/L 105 ± 4 8 ' 
Я аіио 
238 ± 93 NS 
126 ± 63 P-C0.05 
112 ± 7 7 NS 
F E T . m v , % 
F E p a m y , % 
FEsamy, % 
2 4 3 ± 0 74 
4 07 ± 1 2 4 
1 02 ± 0 5 4 * 
2 71 ± 1 6 3 
3 31 ± 1 94 
2 0 6 ± 1 4 1 « 
NS 
P < 0 01 
P < 0 001 
PIS rano 6 58 ± β ΟΣ" 2.09 ± 1 38 е Ρ <0 001 
(median) (3 53) (1 60) 
Abbreviations Ρ = pancreatic, S = salivary, FETvIrt = ІгасІюпаІ excretion or 
total amylase, FEp.^ - Iracttonal хсг іюп of pancreatic amylase, FESarrf -
fractional excretion of salivary amylase. P/S ratio - FEp^FEa,^, NS, not 
sigmlicant " n - e f . ^ n ^ S O , =n = 28 
excretions of S-amylase could only be determined in 50 of 
the 63 normal controls. By contrast, vmnary S-amylase 
could not be demonstrated in only one of the 29 patients. 
When we compared the 50 individuals with detectable 
unnary S-amylase and the 11 individuals with undetectable 
urinary S-amylase we found a significant difference in 
serum isoenzyme pattern. The percentage of P-amylase in 
serum was 47.0 ± 15 8% in the former and 62.8 ± 12 5% in 
the latter group (P <0 01), whereas results for total amylase 
in serum were not significantly different (187 ± 60 and 206 
± 54 U/L, respectively). 
It is evident from Table 1 that, in the patients with renal 
disease, the fractional excretion of P-amylase was signifi­
cantly less than in controls, whereas the fractional excretion 
of S-amylase was significantly greater. As a result the ratio 
of fractional excretion of P-amylase to fractional excretion of 
S-amylase (P/S ratio) was significantly lower, with a median 
value of 1.60 (range 0 66-6.71), as compared with 3 53 
(range 1.79-49.5) for the normal controls (P <0 001) In the 
patients, fractional excretion of amylase and amylase isoen­
zymes correlated significantly with proteinuria (ГЕтщпу vs 
proteinuria: r = 0.49, Ρ <0.02, FEp^ny vs proteinuria г = 
0.53, Ρ <0.01, FEs^j, vs proteinuria: r = 0 54; Ρ <0.01). 
Fractional excretion of total amylase correlated significant­
ly with creatinine clearance (Figure 1). 
The fractional excretion of amylase isoenzymes similarly 
correlated with creatinine clearance (FEs,^ vs ECC: г = 
-0.48; Ρ <0.01; FEp^, vs ECC: r = - 0 67, Ρ <0 001) In 
the 22 patients in whom we measured the unnary excretion 
of ^-microglobulin (UftM), we found a significant correla­
tion of this rate with creatinine clearance (r = - 0 69; Ρ 
<0.001) In these patients the fractional excretion of total 
amylase and amylase isoenzymes also correlated signifi­
cantly with unnaiy /äjM excretion (FEq-^,, vs UftM г = 
0 60; Ρ <0 01, FEs^y vs UftM . г = 0.59, Ρ <0 01, FE P a m y 
vs UftM: r = 0 67, Ρ <0 001) The patients could be divided 
according to /^microglobulin excretion rate (Table 2). In 
nine patients ftM excretion was normal or only slightly 
increased (<1.5 μg/mln; mean 0 36 ± 0 13 μg/mln) In the 
others, ßjM excretion clearly exceeded 15 /ig/nun (mean 
22 5 ± 19 6 fig/mm) On comparing these groups of patients 
we observed a significantly lower creatinine clearance ac-
companied by significantly increased fractional excretions of 
total amylase, P-amylase, and S-amylase in the group of 
patients with the high unnary ftM excretion. The P/S ratio 
was not different, however. When we categorized patients 
according to their original renal disease, the P/S ratio was 
lowest in patients with minimal-lesions glomerulonephntis 
(P/S ratio = 1 37 ± 0.26; η = 4), as compared with 2 00 ± 
0 44,2.25 ± 0.91, and 2.67 ± 0.43 in patients with membra­
nous glomerulonephntis (n = 11), focal glomerulosclerosis 
(n = 6), and proliferative glomerulonephntis (n = 5), 
respectively. 
Discussion 
For the normal volunteers the fractional clearance of total 
amylase averaged 2.4%, a value similar to those reported in 
the literature, which range from 1 24 to 3 1% (J, 10-16). 
Fractional excretion of P-amylase was 4 07%, a value higher 
than those reported in the literature, which range from 1 75 
to 3 5% « i , 12, 14, 17-19) The fractional excretion of P-
amylase exceeded that of S-amylase by three- to fourfold 
This preferential loss of P-amylase in control subjects has 
already been reported, ratios of the fractional excretion of P-
amylase and fractional excretion of S-amylase reportedly 
range from 1 6 to 6 (І2,12,14,16-21) The differences in the 
results of these studies can partly be explained by method­
ological differences, several different techniques having 
been used to determine amylase isoenzymes, e.g, cellulose 
acetate electrophoresis (12), diethylaminoethyl ion-ex­
change chromatography (14,21), Polyacrylamide gel electro­
phoresis (16), and thin-layer isoelectric focussing (17, 18). 
However, ODonnell and coworkers (11,19) found values of 
2.64% and 1.64% for the fractional excretion of P- and S-
Table 2. Results of Amylase Measurements In Patients 
with Renal Disease In Relation to ^-Microglobulin 
( U f t M ) Excretion Rate 
Fig 1 Correlatori ol fractional excretion o( total amylase (FEr-my**·) 
wrth endogenous creatinine clearance (ECC) in palienls 
ECC. m U m i n 
F E T . m l „ % 
F E p ^ y , % 
F E s ™ , , % 
P/S ratio 
(median) 
Abbreviations ECC 
bons, see Table 1 
U f t M < 1 s 
і щ / т і п 
<π = »> 
114 ± 2 9 
1 55 ± 0 6 3 
1 9 6 ± 0 74 
1 18 ± 0 67 
2 3 0 ± 1 84 
(2 07) 
U f t M >1.S 
(la'mln 
(n = 13) 
59 ± 3 3 
3 4 4 ± 1 7 6 
4 27 ± 2 09 
2 62 ± 1 60 
2 06 ± 1 37 
( 1 5 6 ) 
P-vilu· 
P < 0 01 
P < 0 01 
P < 0 01 
P < 0 0 2 
N S 
endogenous creatinine clearance For other abbrevia-
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amylase, respectively, and they used an inhibitor technique 
similar to ours We cannot easily explain the differences 
between results of their and our study, but two points need 
to be considered First, they determined amylase in serum 
and unne samples that had been stored at - 2 0 °C for five 
days Second, for their control subjects they found values for 
P-amylaee in serum (averaging 65% of total amylase) that 
clearly exceeded values reported by others, which range 
from 40 to 50% (10,12, 14, 16, 17, 21-24) 
Some of these authors also used an inhibitor technique 
(23,24) It can be expected that in the subjects of O'Donnell 
et al the proportion of P-amylase in unne as compared to 
total amylase would easily exceed 90% At this high per­
centage of unnary P-amylase the inhibitor method is insen­
sitive (25) and measurements will give falsely high values 
for S-amylase (8) In this respect, it is important to note that, 
m our study, fractional excretion of both amylase isoen­
zymes could be determined in only 50 of the 63 volunteers 
(79%), and in 11 subjects we could detect no S-amylase in 
unne In these subjects, serum P-amylase (expressed as 
percentage of total amylase) was significantly higher In 
view of the higher clearance of P-amylase it can be calculat­
ed that the percentage of P-amylase relative to total amy­
lase in the unne will exceed 90% in these subjects 
In the patients with renal disease and proteinuria, frac­
tional excretion of P-amylase was decreased and that of S-
amylase was increased as compared with control values In 
the patients, the fractional excretions of amylase and amy­
lase isoenzymes were negatively correlated with ECC, m 
agreement with others (10,12,13,15,19) This finding can 
be explained by the decrease of tubular reabsorptive capaci­
ty as renal insufficiency progresses Companng patients 
with normal and abnormal tubular function, we observed no 
differences in the PIS ratio This indicates that both isoen­
zymes are processed by the glomerular tubules in the same 
way Therefore, the current opinion of most authors that the 
differences in unnary excretion of P-amylase and S-amylase 
are a consequence of difference m tubular reabsorption is 
not supported by our results 
The restncted transport of S-amylase must be attnbuted 
to its negative charge, which is consistent with recent 
observations that the net electnc charge on a molecule is an 
important determinant of its fractional clearance (6, 7) The 
decreased fractional excretion of P-amylase in patients with 
protemuna fits well with recent findings that the transglo-
merular transport of neutral dextrans of 2 0-4 6 nm size is 
restncted in patients with nephrotic syndrome (26) The 
relative increase of fractional excretion of S-amylase points 
to a defect in the charge selectivity of the glomerular 
capillary wall Such a defect has been demonstrated in 
several experimental models of glomerulonephritis and in 
humans with diabetes mellitus, congenital nephrotic syn­
drome, and minimal-lesions glomerulonephritis (6) In 
agreement with the latter observations, the PIS ratio was 
lowest in the patients with minimal-lesions glomerulone-
phntis It seems worthwhile to study further the possible 
usefulness of fractional excretions of P- and S-amylase as 
markers of glomerular basement membrane charge 
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Creatinine is the most widely used marker of glomerular filtration rate in general 
clinical practice. The reciprocal of serum creatinine can be used to examine the time 
course of glomerular filtration rate. We review normal production and excretion of 
creatinine and discuss factors which may invalidate the use of creatinine as a marker 
of glomerular filtration rate. Neth J Med 1988;33:144-153. 
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Introduction 
The glomerular filtration rate (GFR) is an important parameter of renal function 
Theoretically, GFR can be measured reliably by determining the renal clearance of 
substances which meet with the following criteria completely filterable at the 
glomerulus, no binding to plasma proteins, absence of metabolism, no tubular 
reabsorption or secretion [1] Examples of markers used for measurement of GFR 
are inulin, [51Cr]EDTA (ethylenediaminetetraacetic acid), and [99Tc]DTPA (diethyl-
enetnaminepentaacetic acid) However, clearance measurements using these exoge-
nous substances are impractical in routine clinical practice because of the need for 
intravenous administration, the collection of multiple blood (and sometimes urine) 
samples, the use of radioactive materials, or the involvement of time consuming 
laboratory techniques Since creatinine has none of these disadvantages, and largely 
satisfies the above-mentioned criteria, it is not surprising that it is still widely used 
as a marker of GFR In recent years, the reciprocal of serum creatinine (1/Screat) 
has become popular for examining changes in renal function in time and for 
assessing the possible effects of therapeutic interventions [2,3] However, as will be 
discussed below, several pitfalls exist in the use of creatinine as a marker of GFR 
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Production and Clearance of Creatinine 
The creatinine precursor creatine is derived from three amino acids arginine, 
glycine, and S-adenosylmethionme [4] Two enzymatic steps are involved in the 
formation of creatine, which primarily takes place in the kidney, liver, and pancreas. 
Creatine is selectively incorporated in muscle and partly phosphorylated to phos-
phocreatine (Fig 1) This phosphocreatine is an important source of phosphate, 
used for the regeneration of adenosine triphosphate (ATP) after muscle contraction 
Since 90-98% of body creatine is stored in muscle, and its concentration in muscle 
is relatively fixed, the total body pool of creatine is relatively constant and 
dependent on total muscle mass Creatine and phosphocreatine are non-enzymati-
cally dehydrated to creatinine at a constant rate, averaging 1.7%/24 h [4,5]. Since 
creatinine has a low molecular weight (MW 113), and is not bound to plasma 
proteins, it is completely filterable at the glomerulus. Under normal circumstances, 
metabolism is negligible while tubular transport contributes less than 20% to overall 
creatinine clearance [6,7]. Thus, GFR can be estimated by determining creatinine in 
blood and in a timed urine sample and by calculating the renal clearance of 
endogenous creatinine (ECC) according to the formula: 
Ucreat 
ECC = Ζ. X V, 
Screat 
where Ucreat = concentration of creatinine in unne; Screat = concentration of 
creatinine in serum; V = urine flow rate (ml/mm) 
As mentioned above, the production and consequently the urinary excretion of 
creatinine are relatively constant and largely depend on muscle mass and thus on 
sex, body weight, and age [8,9]. In recent years, formulae have been developed for 
the estimation of ECC in adults from serum creatinine, sex, body weight, and age 
glycocyomme + methionine 
creatinine 
Fig 1 Creatine production and metabolism Adapted from [4] 
TABI E l 
Formulae for estimation of ECC in adults 
Males Females Ref 
(140 age) x body weight ^ ^ 
0 81 X Screal 
X + (55-z%e) (0 005) X y + (56-age) (0 005) Y 8 
У = 0 4 3 4 Screat l l 
9 8 - 1 6 ( a g e 2 0 ) 
0 0113 X Screat 
2 0
 X090 11 
Age years body weight kg serum creatinine (Screat) μπιοΐ/ΐ 
[8,10,11] In the studies mentioned in Table 1, the estimated values of ECC 
correspond well with measured ECC However, the prediction error (expressed as a 
percentage of ECC) is considerable, exceeding 20% in one-third of the patients [8] 
Furthermore, in patients with liver disease calculated values overestimate measured 
values [12], probably as a consequence of a decrease in creatine or creatinine 
production in these patients In a given patient, creatinine excretion (Ucreat XV) 
can be considered constant in time Therefore, changes in ECC will be paralleled by 
changes in the reciprocal of serum creatinine (1/Screat) This ratio is now widely 
used to follow renal function in time [2,3] In patients with progressive renal 
insufficiency, 1/Screat has been shown to decrease linearly with time [13], allowing 
us to predict the time of end-stage renal failure The time course of 1/Screal is also 
being used to assess the effects of therapeutic interventions on the progression of 
renal insufficiency [2,3] It is important to note that the above-mentioned calcula­
tions and estimations are restricted to situations with only slow changes in renal 
function, where production and excretion of creatinine are in balance However, in 
cases where renal function changes rapidly, such as acute renal failure, serum 
creatinine can easily be used to give quantitative information on the course of renal 
function impairment [14] 
Pitfalls involved in the use of creatinine as a marker of GFR 
A survey of confounding factors influencing serum creatinine and urinary 
creatinine excretion is given in Table 2 The most important factors will be 
discussed below 
Creatine and creatinine derived from exogenous sources Creatine and creatinine 
are not only derived from endogenous production Meat is an important dietary 
source of creatine [15] This creatine is partly converted to creatinine by heating, a 
process which is dependent on the duration of heating and the temperature reached 
(Table 3) Eating of boiled or baked meat can cause up to a two-fold increase of 
serum creatinine 2 to 3 h later [16] Apart from these acute effects, dietary meat 
content can also influence long-term creatinine excretion by changing the total body 
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TABLE 2 
Factors lhal impair the reliabihly of serum creatinine or creatinine clearance as a precise measure of 
glomerular filtration*. 
Factor Magnitude 
of effect (%) 
Cause Influence on 
Screat ECC 1 /Screat 
Strenuous exercise 
Dietary protein intake 
(high protein) 
(low protein) 
Renal disease 
Severe infection, fever, 
trauma 
Drugs 
tnmethopnm, Cimetidine 
Acetoacetate 
Muscular atrophy 
5-
10-
10-
20-
20-
20 
0-
0-
10 
• 30 
30 
-100 
-100 
-100 
-100 
A 
В 
A 
В 
D 
В 
С 
A 
χ 
+ 
X 
+ 
X 
+ 
+ 
+ 
+ 
Screat = serum creatinine; ECC = endogenous creatinine clearance; A = increased/decreased production 
of creatinine from endogenous or exogenous sources; В = increased/decreased tubular secretion of 
creatinine, С = interference with creatinine determination; D = increased extrarenal clearance of 
creatinine; Î = increase; | = decrease; + = overeslimation of glomerular filtration rate; - = 
underestimation of glomerular filtration rate, X = unchanged 
* For references see text. 
creatine pool. An increase or reduction in dietary meat intake of 100 g/day, 
equalling 450 mg of creatine, will alter urinary creatinine excretion by 3.5 mmol/day 
or approximately 25% of normal creatinine excretion. Because of the slow turnover 
rate of creatine, changes in dietary creatine content will lead to gradual changes in 
urinary creatinine excretion. This has been demonstrated by Bleiler and Schedi in 
healthy volunteers [17]: after introduction of a creatine-free diet, urinary creatinine 
excretion decreased by 30-40%. A new steady state was reached only after 6 to 8 
TABLE 3 
Creatine and creatinine content of different meats prepared by different methods * 
Meat 
Round steak 
Lamb 
Perch 
Method of cooking 
Uncooked 
Boiled in water 
Baked in moist heat 
Baked in dry heat 
Baked in moist heat 
Baked in moist heat 
Creatine 
content 
(mmol/100 g) 
3.74 
0 31 
Creatinine 
content 
(mmol/100 g) 
0 371 
1.36 
1.77 
2 86 
151 
0.66 
* According to Cámara et al [15]. 
52 
wk Also, a parallel decrease of serum creatinine was noted from a mean value of 
120 μπιοΐ/ΐ to 90 μπιοΐ/ΐ Similarly, in patients with renal insufficiency, the 
introduction of a low protein diet (0 2 g protein/kg body weight/24 h) caused a 
decrease of serum creatinine from 930 ± 341 μιηοΐ/ΐ to 688 ± 324 μπιοΐ/ΐ (mean ± 
SD) [18] This decrease of serum creatinine concentration was paralleled by a 
decrease of urinary creatinine excretion, implying that ECC remained unchanged 
Use of the reciprocal of serum creatinine as an indicator for FCC would have 
suggested an amelioration of renal function It is important to consider these dietary 
effects when using 1/Screat as an equivalent of ECC Recent studies have claimed 
beneficial effects of early protein restriction on the progression of renal disease [2,3] 
In these studies 1/Screat has been used to evaluate renal function Reduction of 
meat intake per se would be expected to increase 1/Screat thus suggesting an 
amelioration of renal function Indeed, in their study, Mitch et al [2] have 
demonstrated that in the subgroup of their patients, in whom creatinine excretion 
was also measured, 1/Screat suggested an improvement of renal function, whereas 
the measured ECC actually decreased 
Tubular handling of creatinine In man, there is clear evidence of tubular secretion 
of creatinine [19] Under normal circumstances, up to 20-30% of creatinine excre­
tion is caused by tubular secretion [7], leading to a ratio of ECC/GFR of 1 2-1 3 
Transport of creatinine is an active, saturable process, probably located in the 
proximal tubule [19,20] Tubular secretion can be inhibited by both anionic and 
canonic substances [21-26] The latter group is clinically important because it 
includes frequently used drugs such as trimethoprim [22,23], Cimetidine [24 25], and 
salicylates [26] Administration of these drugs will lead to an increase of serum 
creatinine, suggesting a decline of renal function, while measurement of GFR 
reveals no changes Tubular secretion of creatinine can also be stimulated Adminis­
tration of creatinine has been demonstrated to enhance its own tubular secretion 
[19] In line with this, we recently found changes of tubular creatinine secretion in 
patients with renal disease when the protein intake was modified In 8 patients who 
adhered to a high protein diet for 4 wk and were then switched to a low protein diet 
for another 4 wk, GFR (inuhn clearance) did not change significantly However, the 
ratio ECC/GFR which can be used as a measure of tubular creatinine secretion 
decreased significantly from 1 60 ± 0 04 (mean ± SEM) on the high protein diet to 
1 48 ± 0 04 on the low protein diet ( Ρ < 0 05, Fig 2) Similarly, tubular secretion of 
creatinine is increased in patients with renal insufficiency [27] This partly offsets 
the expected rise in serum creatinine when GFR decreases, so that a significant rise 
in serum creatinine is not observed before GFR decreases below 60 ml/min [27] 
Furthermore, ECC will overestimate GFR more as renal insufficiency progresses 
(Fig 3). Some authors claim that tubular secretion of creatinine is even more 
important in patients with a nephrotic syndrome [28], but this is denied by others 
[29,30] Changes in tubular secretion may explain why small changes in GFR will be 
undetectable when using ECC [3] Although tubular reabsorption of creatinine has 
been demonstrated in rats, and has been suggested by experiments in sheep, goats, 
and dogs [20,32], in man only circumstantial evidence points to the possibility of 
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ECC/GFR-
Ι β Γ p < 0 0 5 
^ 
Fig 2 Ratio ECC/GFR in patients with renal disease on a high protein diet (HP) and a low protein diet 
(LP) (Personal observations GFR was measured using inulin clearance Creatinine was measured using 
dlkabne picrate ) 
ECC/GFR-
ЗОг 
? О 
1 0 
• о 
Г : - О 74 
р < 0 001 
о Э-1 
5 0 100 
(jFR (ml/ mm) 
150 
Fig 3 Ratio ECC/GFR in relation to renal function (GFR) ECC overestimates GFR more as renal 
insufficiency progresses (Personal observations GFR was measured using inulin clearance in healthy 
volunteers (o) and patients with renal disease ( · ) Creatinine was measured using alkaline picrate ) 
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TABLE 4 
Substances interfering with the determination of creatinine using alkaline picrate. 
Acetoacetate [38,43] 
Oxaloacetale [43] 
Pyruvate [43] 
Cephalosporins [45,46] 
Non-creatinme chromogens [7] 
Methyldopa [47] 
Bilirubin [42] 
Numbers in brackets refer to the references. 
tubular reabsorption of creatinine [33,34]. Further studies are needed regarding this 
subject. 
Metabolism of creatinine. In healthy volunteers and patients with normal renal 
function, metabolism of creatinine is negligible, over 98% of creatinine being 
recovered in the urine [6]. However, in patients with renal insufficiency, more 
substantial metabolism of creatinine has been demonstrated [6,35]. The degradation 
rate is correlated with the serum creatinine concentration, and in patients approach-
ing end stage renal failure, up to 65% of creatinine may be metabolized, probably in 
the gut [35]. This explains the decrease of 24 h urinary creatinine excretion noted in 
patients with renal insufficiency, which cannot be accounted for by changes in 
muscle mass or age [36]. In such circumstances, use of 1/Screat will overestimate 
ECC. 
Interference with determination of creatinine. Most laboratory procedures for 
determining creatinine, including current auto-analyzer techniques, are based on the 
reaction of creatinine with alkaline picrate described more than a century ago [37]. 
However, this colorimetrie reaction is not specific and many substances may 
interfere (Table 4). Normal serum always contains a certain amount of substances 
which react with alkaline picrate to produce a red colour. These so-called non-
creatinine chromogens contribute 20% to total measured creatinine. In renal insuf-
ficiency the contribution of non-creatinine chromogens becomes less important [7]. 
Clinically important is the interference of aceto-acetate with creatinine determina-
tion. In patients with diabetes mellitus and ketoacidosis, and in patients after 
prolonged fasting, spurious increases of serum creatinine concentrations up to 
two-fold may be found [38-40]. In these instances, renal function is underestimated 
when using creatinine as marker of GFR. Many procedures and techniques have 
been developed which more or less circumvent these problems by measuring 
creatinine very specifically [41-43]. It is important to be aware of the possibility of 
interference and to check one's own laboratory method in this respect. 
Other factors influencing serum creatinine and urinary creatinine excretion. In 
Table 2, several remaining factors are mentioned which may influence serum 
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creatinine and urinary creatinine excretion apart from a change in muscle mass or 
renal function. Creatinine production and excretion are increased after severe 
trauma, major surgery, and in cases of fever and sepsis [44]. A decreased creatinine 
excretion out of proportion to body weight is found in patients with excessive 
muscle wasting or severe muscular atrophy (immobilisation, neurological diseases). 
In the above-mentioned circumstances, serum creatinine will not reflect ECC, and 
may lead to a definite over- or underestimation of renal function. 
Conclusion 
Endogenous creatinine clearance is only a rough estimation of GFR. When 
precise information is needed, especially when studying small effects of therapeutic 
interventions, more invasive techniques should be used. However, in routine clinical 
practice a rough estimate of renal function will usually suffice. In these cir­
cumstances, determination of serum creatinine will almost always provide the 
required information, provided the possible pitfalls as mentioned in this review are 
taken into account. 
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Abstract. We studied the effect of prednisone on urinary protein excretion in 19 patients with a nephrotic 
syndrome, who were treated with prednisone (125-150 mg) on alternate days We found a typical, fluctuating pattern 
of proteinuria resulting from an increased protein excretion rate on prednisone days and a decreased protein 
excretion rate on nonpredmsone days The urinary protein excretion on prednisone days was 9 9 ± 3 3 g/24 h, as 
compared to 5 7 ± 3 8 g/24 h on nonpredmsone days (mean ± SD) In the whole group of patients the perceptual 
change in proteinuria was significantly correlated with the endogenous creatinine clearance However, systematic 
differences between creatinine excretion rates on prednisone and nonpredmsone days were not found in individual 
patients In 6 patients, renal hemodynamics were studied more precisely, using a single injection technique Only a 
slight and nonsignificant decrease in glomerular filtration rate was found on nonpredmsone days (Л = -9 6± 16 3%. 
mean ± SD) P-illralion fraction remained unchanged It is therefore suggested that the effects of prednisone on 
proteinuria are not simply mediated by overall changes in renal hemodynamics 
Glucocorticoid treatment is regularly used in patients 
with a nephrotic syndrome [I, 2] Its therapeutic efficacy 
in patients with 'minimal change' disease is well esta­
blished [3, 4] A rapid decrease in urinary protein excre­
tion rate can be observed in most of these patients In 
1979, beneficial effects of prednisone (P) treatment were 
reported in patients with membranous nephropathv [5] 
The authors advised to use an alternate-day regimen, in 
order to reduce side effects 
There are a few reports in which mention is made of an 
increase of urinary protein excretion after administration 
of corticosteroids [6, 7] However, after the initial obser­
vations in children of Heymann and Grupe [7], the phe­
nomenon has not received further attention While treat­
ing patients with a nephrotic syndrome according to the 
above mentioned Coggins' scheme [5], we observed an 
increase of proteinuria on Ρ days [8] We have tried to 
gam a better insight in this effect by carrying out syste­
matic studies in more patients As Ρ causes changes in 
renal hemodynamics in experimental animals and in man 
[9, 10], which could be responsible for the effects ob­
served, we have carried out additional, more precise 
measurements of glomerular filtration rale (GI-R) and 
effective renal plasma flow ( LR Ph) Our study shows that 
administration of Ρ in an alternate day regimen results in 
a typical fluctuating pattern of proteinuria, due to an 
increased protein excretion rate on Ρ days and a de­
creased protein excretion rate on nonpredmsone (NP) 
days The latter has not been described before and ap­
pears to be an independent phenomenon related to the 
withdrawal ofcorticosteroids The results of the hemody­
namic studies suggest that the observed fluctuations of 
protein excretion are not mediated by alterations in G \· R 
or ERPF 
Materials and Methods 
We studied 19 patients with a nephrotic syndrome, with a mean 
age of 42 I years (range 1^-72), and a mean endogenous creatinine 
clearance (ECC) of 109 ml/mm (range 33 220) Clinical data are 
presented in table I All but 3 patients had a membranous glomeru 
lonephntis Palient No 17 was treated because of sarLOidosis In 
patient No 16 an erroneous diagnosis of membranous nephropathy 
was made initially Patient No 2 who was treated because of a 
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Table I Glimcdl dáU 
Pa 
tient 
I 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
IS 
16 
17 
18 
19 
Sex 
M 
F 
M 
M 
M 
F 
M 
F 
M 
F 
M 
M 
M 
F 
M 
F 
M 
M 
F 
Age 
15 
29 
37 
33 
34 
46 
65 
16 
48 
22 
52 
54 
" 29 
36 
45 
41 
66 
61 
72 
Diagnosis 
MG 
ML 
MG 
MG 
MG 
MG 
MG 
MG 
MG 
MG 
MG 
MG 
MG 
MG 
MG 
FSPG 
FGS 
sarcoidosis 
MG 
MG 
ECC 
ml/mtn 
220 
175 
156 
150 
148 
i l 4 
125 
125 
117 
117 
115 
103 
100 
72 
62 
45 
42 
35 
33 
Other medication 
_ 
chlonhalidone 
propranolol 
Cimetidine 
_ 
Cimetidine 
Cimetidine 
chlorthalidone 
furosemide 
Cimetidine 
furosemide 
Cimetidine 
Cotrimoxazol 
Cimetidine 
furosemide 
furosemide digoxin 
furosemide 
M =- male F- = female MO — membranous glomerulonephniis 
ML= minimal lesions FSPG = focal segmenial proliferative glom 
eruloncphntis FGS = focal glomerulosclerosis ECC-endoge 
nous creatinine clearance 
A total of four 24 hour urine samples were considered to be 
collected incompletely as judged by a 40 50% decrease in creatinine 
extrelion These samples were excluded from the talculations ECC 
were calculated from creatinine values measured in serum and in 
24 hour urine samples 
In 6 patients we measured GFR and E RPF* using a i ingle 
injection technique [II] ' 1 lodothalamate and Jll hippuran clear 
anees were used as markers for GFR and ERPF respectively After 
rapid intravenous injection ol the markers blood samples were 
drawn regularly during a 4 hour period In all cases the terminal 
monocxponential part of the curve was reached in some later than 
expected probably due lo a decreased renal function and/or an 
increased volume of distribution due to the edema [12] In these 
patients analysis of the plasma disappearance curve according to an 
open two compartment model [13] could overestimate the renal 
clearance [14 15] We therefore analyzed the plasma disappearance 
curves according to both a two and a three companment model 
except for two ERPF curves that could not be fitted well according 
to a three compartment model As expected renal clearances using 
the three compartment model were lower (GFR mean Δ = -10 9ί,ο 
ERPF mean Δ= ΙΙ80ο) Both methods correlated well (GFR 
r = 0 99 ERPF r = 0 98) Therefore we chose the values obtained 
with the most commonly used two compartment model In all 
patients measurements were done on a Pday anda NPday 5 da\s 
after starting therapy In 5 patients we did additional measurements 
immediateK before starting therapy (control measurements) In 1 
patient measurements were repeated 2 months after starting ther 
ap> All measurements were started at 13 00 h On Ρ days Ρ was 
administered 8 h before the start of the isotope study (at 5 00 h) All 
patients gave informed consent and thev received KI 100 mg/day 
to protect the thyroid from radiation damage 
For statistical analysis we used Wilcoxon s rank sum test and 
Student s I lest when appropriate Linear regression was calculated 
using the Spearman correlation 
minimal change disease is included because of the steroid resis 
tant nature ofher nephrotic syndrome 
All patients were admitted to the hospital and treated with Pin 
an alternate day regimen[5] Ten patients reccivedl25 mg of Pevery 
other day thc9otherpatients in whom body weight exceeded 80 kg 
received 150 mg of Ρ Protein and creatinine excretion in 24 hour 
urine samples were measured on Ρ and NP days In 4 patients the 
time course of proteinuria after intravenous prednisolone adminis 
tration was studied by sampling unne 4 hourly during 6 consecutive 
days Comparison with pretreatment values of protein and creati 
nine excretion was possible in 10 patients who met with the follow 
mg criteria (a) at least two 24 hour unne samples collected within 
(he hospital immediately before starting Ρ treatment and (b) no 
change in concomitant medication (patients in whom Cimetidine 
treatment was started together with Ρ treatment were thus ex 
eluded) 
Creatinine concentrations in unne and serum were determined 
using Jaffe s method Urinary protein excretion was measured using 
the biuret method Percentual changes of proteinuria between Pand 
NPdays were calculated using the following formula 
Mean proteinuria Ρ days - mean proteinuria NPdays .-^ 
(Mean proteinuria Ρ days + mean proteinuria NP days) 2 
Results 
The time course of proteinuria in 1 patients after 
intravenous administration of prednisolone is shown in 
figure 1 A rapid increase of protein excretion was found 
reaching its maximum 8-12 h after administration of 
prednisolone No concomitant changes in creatinine 
excretion rates could be found Administration of Ρ in an 
alternate day regimen resulted in a typical fluctuating 
pattern, as shown in figure 2 for all patients (mean num 
berofobserved Pand NPdays 12 4,range6-20days) The 
urinary protein excretion on Ρ days was 9 9 ± 3 3 g/24 h 
(mean ± SD), as compared to 5 7 ± 3 8 g/24 h 
(mean ± SD) on NP days (p<0 001) The fluctuations 
remained present during the whole observation period 
The figure could suggest that protein excretion decreased 
with time This however was not the case The apparent 
decrease of overall protein excretion was due to the fact 
that patients with the longest observation period had a 
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Fig. 1. Mean protein and creatinine excre-
tion in 4-hour urine samples on Ρ days 
(hatched bars) and NP days (open bars) in 3 
patients Urine samples were collected on 6 
consecutive days Values are given as means ± 
SD 
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Fig. 2. Mean protein and creatinine excre­
tion in 24 hour urine samples, before and dur­
ing Ρ therapy of all patients studied Ρ admin­
istration was started at day 1 Hatched bars 
represent Ρ days, open bars represent NP 
days Values arc given as means ± ShM The 
number of patients is given m parentheses 
Proteinuria lg/2¿h) 
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Fig. 3. Protein excretion rate on the first Ρ day (hatched bars) and 
the consecutive Ρ days (open bars) in patients without and with 
diuretic treatment. Values are given as means ± SEM 
lower protein excretion rate. In individual patients no 
diminution of proteinuria on Ρ or NP days was observed. 
In 2 patients (Nos. I and 11) in whom we measured 
proteinuria when tapering the Ρ dose, differences in 
protein excretion rates could still be observed with a dose 
as low as 15 mg every other day. 
Figure 2 shows that proteinuria on the first Ρ day 
exceeded that on the following Ρ days. On further ana­
lysis, this difference appeared to be significant only in 
patients not using diuretics (fig 3) Patients without di­
uretics (n = 8) had a mean ECC of 145 ±37 ml/mm, 
whereas in patients with diuretics (n = 5) the ECC was 
85±52 ml/min (mean±SD; p = 0.07). Within each 
group there was no correlation of fcCC with the differ­
ence in proteinuria between the first and subsequent Ρ 
days. 
In 10 patients the protein excretion rate on Ρ and NP 
days could be compared with control protein excretion 
rates measured immediately before the start of the treat­
ment (fig. 4). The increase of protein excretion on Ρ days 
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Fig 4 Percentual change in protein excretion rate on Pda>s 
(hatched bars) and NP da>s (open bars) as compared to pretreat 
ment values Patients are arranged according to ECC 
Fig 5 Relationship between percentual fluctuations of protein 
una and the hCC 
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Fig 6 Results of GFR and FRPf-measurements in 6 patients 
The patient number is given at the right ofeach curve Patient 19 was 
measured twice 
high ECC ( » 1 0 0 ml/mm) It should be realized that 
patient No 2 with'minimal change disease is included in 
this study Although this patient did not reach a remission 
during treatment, it is possible that a partial therapeutic 
effect of Ρ was responsible for the decrease of proteinuria 
on Ρ days 
The percentual change of protein excretion between Ρ 
and NP days in individual patients was significantly 
correlated with the ECC (fig 5) A similar correlation 
with EC ( was found for the decrease ofprotem excretion 
on N P days as compared to pretreatment values How­
ever, urinary creatinine excretion rates on Ρ and N P days 
were not different (P days 13 6 ± 3 2 mmol/24 h, N P 
days 13 8 + 3 ( ) m m o l / 2 4 h , m e a n ± S D ) Resul t sofGER 
and ERPE measurements are shown in figure 6 Differ­
ences are small, GER on N P days tending to be lower 
than on Ρ da>s (Δ = -9 6 ± 1 6 3%, m e a n ± S D p = 0 10) 
No significant changes in filtration fraction (i e G E R / 
ERPE) were observed 
Discussion 
( Δ = + 2 5 9 ± 3 8 3%, mean ± SD) was less consistent 
than the decrease of protein excretion on N P days 
( Λ = 43 9 ± 1 8 6%, mean ± S D ) In patients with a high 
ECC (ECC > 125 ml/min), the increase in proteinuria on 
Ρ days seems less pronounced The decrease of protein 
excretion on N P da>s was not correlated with the in­
crease of protein excretion on Ρ days, neither in the whole 
group, nor in the subgroup of patients with normal or 
Our study partly confirms earlier observations of a 
corticosteroidinduced increase in proteinuria [6, 7] In 
Heymann and Grup s study [7] a maximal effect was 
found on the first dav, in agreement with our observa­
tions in patients not using diuretics Heymann and d r u p e 
[7] found that during daily administration of P, the pro­
teinuric effect wore off after a few days Using an alter­
nate-day regimen of Ρ administration we observed no 
diminution in P-induced fluctuations of proteinuria dur-
6 4 
ing a treatment period of 2 months A trivial explanation 
for the observed decrease of protein excretion rate on NP 
days might be that the increased protein excretion on Ρ 
days had lowered serum protein concentration Assum 
ing that GFR remained unaltered, this could cause a 
slight decrease in protein excretion on NP days How 
ever, in 4 patients the observed fluctuations in proteinu 
na were caused by a mere decrease of protein excretion 
on NP days, not preceded by an increase on Ρ days 
Moreover, the increase of protein excretion on Ρ days 
was not correlated with the decrease on NP days From 
this we conclude that the decreased protein excretion rate 
on Ν Ρ days is an independent phenomenon related to the 
withdrawal of Ρ 
Although an untreated control group is lacking in our 
stud), it seems unlikely that the fluctuations in protein 
excretion occurred spontaneously Data on 24-hour pro 
(ein excretion in hospitalized patients are scarce In an 
earlier study only slight variations were found [16], as we 
did in 5 patients who were hospitalized from i to 7 days 
betöre starting Ρ therapy In patients studied under stan 
dard conditions with strict bed rest, a gradual decrease in 
24 hour protein excretion on consecutive days is found 
[17] In these patients a circadian rhythm was observed 
with fluctuations of protein excretion within a 24 hour 
period However, the fluctuations that we observed 
would require a 48-hour rhythm in protein excretion 
Such a rhythm was not noted in the last mentioned study 
We therefore feel that the fluctuations wc observed are 
the result of alternate day Ρ administration 
In the rat a glucocorticoid induced increase in protein 
excretion is also found [18), and this has been shown to be 
dose dependent (19] I ime relations differ from our data 
however, the increase reaching its maximum not until 
14-32 h after glucocorticoid administration In the 3 
patients in whom we studied this, the proteinuric etfect 
was already apparent after 4 h and reached a maximum 
after 8-12 h We did not systematically study dose-effect 
relations, but we still noted fluctuations in protein excre­
tion rates in patients receiving Ρ doses as low as 15 mg 
Several factors could be responsible for the observed 
changes in protein excretion rate alterations in renal 
hemodynamics, changes in tubular reabsorption of pro­
tein, or changes in the permselective characteristics of the 
glomerular basement membrane [20] The correlation we 
found between the percentual change in protein excre 
tion and the ECC could be explained by an effect of Ρ on 
renal hemodynamics assuming hyperfiltration in rem 
nant functioning nephrons [21] This hyperfiltration de­
creases the functional reserve capacity ofthe kidney [22] 
Consequently the ability ofthe kidney to increase GFR 
and renal blood flow will be lost in patients with renal 
insufficiency However, a tubular mechanism cannot be 
excluded In renal insufficiency there will be an absolute 
loss of functioning nephrons, and therefore of tubuli If 
compensatory hyperfiltration occurs, FCC will tend to 
overestimate the amount of functioning tubuli Conse 
quently, tubular effects of Ρ will be less prominent in 
patients with renal insufficiency and therefore a similar 
correlation of the percentual change of protein excretion 
and the ECC can be expected 
It is difficult to derive from the data reported in the 
literature whether the proteinuric effect of Ρ is primarily 
glomerular or tubular С hronic administration of gluco­
corticoids increases GFR in animals and man [9, 10, 
23 25] Observations on the acute effects of glucocorti­
coid administration are less straightforward In the rat an 
increase ofGFR is found [18], but in man GFR was found 
to remain unchanged [26]. increased [27], or even de 
creased [28] Glucocorticoids decrease proximal tubular 
reabsorption of water and electrolytes, and probably 
amino acids in man [29-31] In the rat an effect of prednis­
olone on tubular protein reabsorption could not be found 
[18] 
We did not find fluctuations in creatinine excretion 
rates indicating unaltered GFR on Pand NPdays How­
ever, creatinine clearance is an unreliable marker of GFR 
especially in patients with a nephrotic syndrome [32] 
Furthermore, Ρ could inhibit tubular secretion of creati­
nine thus masking any positive effect on glomerular 
filtration of creatinine [28] Therefore, we studied renal 
function more precisely, using a single injection tech 
nique Only minor fluctuations in GFR and ERPF were 
found It is therefore unlikely that the fluctuations in 
protein excretion rates can be explained by changes in 
GFR This is consistent with the findings in the rat, where 
the increase in protein excretion was not accompanied by 
an increase in GFR [18] Since we did not measure GFR 
on the first Ρ day, we cannot exclude an acute hemody­
namic effect of Ρ which would explain the extra increase 
in protein excretion rate on the first Ρ day observed in 
patients not using diuretics Attenuation of this first day 
effect by diuretics suggests alterations in renal hemody­
namics, since diuretics are known to influence F RPF and 
renal autoregulation [33, 34] This phenomenon and also 
the effects of Ρ administration on tubular function de 
serve further study 
Our observations of a consistent decrease in protein 
excretion rate on NP days points to another possible 
mechanism Renin, angiotensin as well as norepineph 
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riñe are known to induce proteinuria [4^-47] Since these 
effects are blocked b) adrenalectomy it is assumed that 
glucocorticoids have a permissive action on generating 
this proteinuria This permissive action of glucocorti 
colds cannol be explained by mere changes in renal 
hemodynamics [48] Assuming such a permissive action 
of glucocorticoids a decrease ol endogenous Cortisol on 
NP d us could have been responsible for the observed 
dicaase in protein excretion rate Bv a similar mecha 
nism the circadian rhythm of endogenous Cortisol pro 
duction might be responsible for the observed 24 hour 
fluctudlions of proteinuria in untreated patients with the 
nephrotic syndrome [17] 
We conclude that Ρ administered in an alternate day 
regimen causes changes in protein excretion rates which 
are not explained bv hemodynamic alterations Further 
studies are necessary to elucidate the responsible mecha 
nisms From a practical point of view it is important to 
realize that transient increases or decreases of protein 
una during treatment with Ρ do not necessarily reflect 
therapeutic failure or success especially when intermit 
tent dosage schedules are used 
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Prednisolone can increase glomerular permeability to proteins 
in nephrotic syndrome 
J A C K F M W E T Z E L S , H E N K E S L U I T E R , A N D R I E S J H O I T S M A , P I E T J J V A N M U N S T E R , 
a n d R O B E R T Α Ρ K O E N E 
Department of Medicine Dnisinn of Sephrolog \ and ΐ abaratan of Pedititnt ι Unii eritl\ Hospital Ni/wicf/i Tin \iliierland\ 
Prednisolone can Increase glomerular permeability lo proteins In 
patients »ith a nephrotic syndrome In patients with a nephrotic syn 
drome adminibtration of prednisolone causes an increase of proteinuria 
To elucidate the mechanism of this effect we have studied the acute 
proteinuric effect of prednisolone I2S to И0 mg intiavcnously in nine 
patients (7 M 2 F) with a nephrotic syndrome Mean age (± so) of the 
palients was 53 ^ 6 years mean endogenous creatinine clearance 104 ± 
30 ml/mm and mean proteinuria 7 7 ± 3 0 g/24 hr After administration 
of prednisolone urinary total protein excretion rose in all patients from 
a mean ( ± S F M ) of 4 89 ± 0 Ί9 mg mm before lo 9 09 ± 0 99 me mm at 
Ave hours after administration (P < 0 01) Glomerular fìllration rate 
(inuhn clearance) effective renal plasma flow (PAH clearance) and 
nitration fraction did not change signifìcantly Ihe increases of urinary 
excretion of albumin (median 9f +92ÇÎ) lg(j (median r i +88^) and 
transferrin (median 9Ï- +76'/f·) were comparable and correlated sigmfi 
canllv Lnnary excretion of fr> microglobulin did not change sigmfi 
cantlv however We conclude that intravenous administration of 
prednisolone to patients with a nephrotic syndrome causes an increase 
in urinary protein excretion rale which cannot be explained by changes 
in renal hemodynamics or tubular protein rcabsorption and which 
therefore must be the result of a change m glomerular permsclcctivuy 
characteristics 
Glucocorticoid treatment is regularly used in patients with a 
nephrotic syndrome due to minimal change disease or membra 
nous nephropathy [1 2] In order to reduce side effects of 
corticosteroid therapy an alternate day regimen has been ad 
vised [2) While treating patients with a nephrotic syndrome 
according to the above mentioned Coggin s scheme [21 we 
observed a typical fluctuating pattern of proteinuria due to an 
increased proteinuria on prednisone days and a decrease on 
non prednisone days [3 4] The increase of proteinuria seemed 
most prominent on the first day of prednisone treatment [4) 
Similar observations of a corticosteroid induced increase of 
proteinuria have been made before in human [5 6J as well as m 
animal studies [7 8] The mechanism of this effect is as yet 
unclear Therefore we have studied the acute effects of 
prednisolone on protein excretion rate in patients with a ne 
phrotic syndrome and concurrently measured changes in renal 
hemodynamics and tubular protein rcabsorption Our study 
demonstrates that prednisolone acutely increases proteinuria 
Received for publication March 11 1987 
and in revised form October I 1987 
© 1988 by the International Society of Nephrology 
without causing changes in renal hemodynamics or tubular 
protein reabsorption This suggests that prednisolone increases 
proteinuria by causing a change in glomerular pcrmselcumty 
Methods 
We studied nine patients with a nephrotic syndrome due to 
idiopathic membranous glomerulonephritis ( \ - 7) or minimal 
change disease ( \ - 2) Mean age (± sDlof Ihe patients was S3 
± 6 years mean endogenous creatinine clearance (ICC) was 
104 30 mi'min and mean blood pressure 141 89 1 14 8 mm 
Hg No patient had evidence of onhosiaiic hypotension Fur 
thcr clinical data of Ihe palients arc presented m Ί able I 
All patients were studied on the day of the start of 
prednisolone therapy All but two patients were admitted to the 
hospital several days before All patients were on a normal 
sodium intake diet containing 100 to IM) mmol Na After a 
light breakfast patients came lo Ihe investigating room at 9 (Ю 
a m where the experiment look place from 9 00 a m till S 00 
ρ m No food was given during the experiment λ firm diuresis 
was established by an initial oral water load of ^00 to 1000 ml 
Thereafter we tried to maintain urinary flow rale above three 
ml mm by giving water orally or infusing а ОД glucose solution 
To keep urinary pH above 6 0 (which is necessary lor correct 
measurement of 0-· microglobulin vide infra) one gram of 
sodium bicarbonate was given at regular intervals ot 60 to 120 
minutes Glomerular hltration rate (GFR) and effective renal 
plasma flow (FRPF) were measured using a continuous infusion 
technique Renal clearances of mulin (Inutest" L aevosan 
GMBH Linz Austria) and para ammohippuratc (PAH) were 
used as markers of GFR and LRPI respectively After an 
equilibration period of 90 minutes urine was collected at 
regular intervals (45 lo 60 mm) for determinalion of inuhn 
PAH sodium total protein albumin transferrin IgG and 
/Si microglobulin (/З^ М) In seven patients urine was collected 
using a bladder catheter in two patients H was collected by 
spontaneous voiding Afler collecting two 4S minute urine 
samples for obtaining base line values prednisolone sodium 
succinate was administered intravenously in a dose of 12^ mg 
(body weight s 75 kg) or 150 mg (body weighi > 75 kg) Afler 
administration of prednisolone a total of five urine samples were 
collected at intervals of 60 minutes Before and at the end of 
every urine collection period blood for determination of inuhn 
PAH and sodium was sampled via a second indwelling venous 
catheter Furthermore in seven patients blood samples were 
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Sex 
M 
M 
M 
M 
M 
F 
M 
M 
F 
Table 
Age 
\еигь 
53 
44 
57 
56 
58 
49 
54 
55 
50 
1 Clinicj] data of Ihe patients 
Diagnosis 
MON 
MGN 
MON 
MGN 
MGN 
MI 
M L 
MGN 
MGN 
ЬСС 
ml mm 
114 
85 
86 
m 
155 
128 
118 
85 
51 
Proteinuria 
ц 24 hi 
8 1 
6 9 
44 
63 
6 9 
58 
12 9 
56 
12 4 
Olher 
medicalion 
pindolol/ 
clopamide 
atenolol 
meloprolol 
— aceno 
toumarol 
— meloprolol 
Abbreviations are M male F female MGN membranous glomeru 
lonephntis ML minimal lesions ECC endogenous (.redimine clear 
ance (delermined from serum creatinine and 24-hr urinary crcaunine 
excretion) 
collected immediately before, and three and five hours after 
administration of prednisolone for determination of albumin, 
transferrin, IgG and ftM 
Sodium, inuhn, and PAII in unne and plasma were measured 
using standard semi-automated techniques Urinary total pro­
tein was measured using the biuret method Albumin, transfer­
rin, and IgG in urine and serum were measured by im-
munonephelometry using specific antibodies raised in rabbits 
Serum and unnary ftM were measured using a commercially 
available radioimmunoassay (Pharmacia) In one patient no 
serum PAH and sodium values could be determined due to 
technical difficulties In another patient urinary ß>M was not 
measured because of a low unnary pH (pH < 6 0) Filtration 
fraction (FF) was defined as GFR/ERPF The fractional excre-
tion (FE) of a substance was defined as the renal clearance of 
that substance divided by the GFR, and expressed as a percent-
age For statistical analysis Wilcoxon's sign rank test was used 
Linear regression was calculated using Spearman's correlation 
coefficient A Ρ value less than 0 05 was considered significant 
Unless otherwise stated all values are given as means ± SFM 
The study protocol was approved by the Hospital Ethical 
Committee AU patients gave informed consent 
Results 
The hydration protocol resulted in a diuresis of more than 3 
ml/mm in all but one patient After administration of 
prednisolone urinary (low rate decreased slightly but signifi­
cantly from 5 0 ± 0 6 ml/min to a lowest mean value of 3 3 * 0 5 
ml/mm (299 ± 38 ml/hrand 197 ± 32 ml/hr, respectively. Fig 1) 
Unnary sodium excretion was also significantly reduced (Fig 
1) F L S j decreased from I 96 ± 0 42% to a lowest mean of 0 63 
± 0 2\r/r (N = 8, Ρ < 0 02) Serum albumin increased signifi­
cantly from 23 9 ± 13 g/liter to 25 9 ± 2 0 g/liter (P < 0 05) 
Similar increases were found for IgG and transferrin (IgG 4 81 
± 0 72 g/liter to 5 13 i 0 80 g/liter, I' < 0 05 Fransfemn 1 81 
¿ 0 22 g/hier to 1 98 ± 0 14 g/liter, Ρ < 0 05) 
After administration of prednisolone urinary total protein 
excretion increased significantly, from a mean value of 4 89 =: 
0 59 mg/mm before to 9 09 - 0 99 mg/min at five hours after 
administration of the drag (293 ± 35 mg/hr and 545 ± 59 mg/hr, 
respectively Fig I) As shown in the figure an increase of 
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Time, mm 
FIR. 1. LfftHli of prednisolone on urinary flou rate (V) sodium 
excretion (U\AVi and proteinuria Prednisolone was administraled at 
lime = 0 mm Baseline values were obtained from -90 lo 0 mm 'P < 
0 05 '*P < 0 01 compared lo mean baseline values 
unnary protein excretion was already apparent at two hours 
after administration of prednisolone Urinary total protein 
excretion increased in all patients, percenlual increases (after 
five hours) ranging from +21% to +1789?- (median -95%) 
The renal hemodynamic effects of prednisolone are shown in 
Figure 2 Although two patients demonstrated a clear increase 
of ERPF at four to five hours after administration of 
prednisolone no significant changes in GFR or ERPF occurred 
overall As a result filtration fraction remained virtually un­
changed dunng the expenment 
Overall effects of prednisolone on the unnary excretion of the 
vanous proteins measured are given in Table 2, showing 
parallel and significant increases of urinary albumin, IgG, and 
transfemn excretion but no significant change in unnary ftM 
excretion The excretion rates for the individual patients of 
urinary albumin, IgG, transfemn, and β;M at the start and 
dunng the last hour of the expenment are shown in Figure 3 It 
is clear from this figure that absolute urinary excretion rates of 
Wetzeh et al Aiuti protemuru effects of prednisolone 
I 
E 500 
400-
prednisolone 
LLLï 
i во 
E 
Τ ί 
120 
Time, mm 
240 
Flg. 2 Acute effects υ/predmwlone on renal hemotl\n(umL\ Abbre 
viations arc OhR glomerular ñltralion rate h RPF eflective renal 
plasma How FF nitration fraition 
albumin, IgG and transferrin rose in all patients Fractional 
excretion of albumin IgG and transferrin (which could be 
calculated in seven patients) also rose in all patients (albumin 
from 0 374 ± 0 0989Í to 0 SVS ± 0 094% Ρ < 0 № IgG Irom 
0 066 ± 0 014% to 0 117 ± 0 036% Ρ < 0 04 transferrin from 
0 316 + 0 095% to 0 561 ± 0 110%, Ρ < 0 05) Percentage 
increases of unnary albumin IgG and transferrin excretion 
were comparable (albumin median Δ% 192% IgG median Δ% 
+88%, transferrin median Δ% -76%) and correlated signifi 
cantly (albumin vs transferrin r - 0 70 Ρ < 0 05, albumin vs 
IgG r = 0 68. Ρ < 0 05 and transferrin vs IgG r = 0 80 Ρ < 
0 01, Fig 4) From Figure 4 it is apparent that the increase of 
unnary IgG excretion exceeded the increase of urinary trans 
femn excretion in seven out of nine patients However, this 
difference was not significant (P = 0 08) As a result selectivity 
of proteinuria (calculated as clearance IgG clearance transfer 
nn) did not change significantly Although overall urinary 
excretion of ^ M did not change significantly (Table I) an 
increase was found in six patients (big 3) The percentual 
increase of unnary β,Μ excretion correlated with the 
percentual increase of urinary IgG excretion (r =• 0 76 Ρ < 
0 05) but was always less The percentual increase of unnary 
ft.M excretion was less than the percentual increase of albumin 
excretion in seven patients (out of eight) Consequently the 
ratio of unnary ftM excrelion/unnary albumin excretion de 
creased significantly from 0 475 ± 0 304 to 0 308 ± 0 174 (P < 
0 05) 
Discussion 
We recently have confirmed earlier observations in humans 
of a corticosteroid induced increase of proteimma [3, 4] To 
elucidate the mechanism of this effect we have studied the acute 
effects of prednisolone in nine patients with renal disease and 
proteinuria 
All patients were on a normal sodium intake when studied 
We noted a slight decrease of urinary flow rate and a firm 
decrease of urinary sodium excretion after administration of 
prednisolone Although high doses of prednisolone have been 
shown to exert mmeralocorticoul effects [9] which could ex­
plain the anlinalnuresis that we observed the decreased uri­
nary flow rate could also be the result of incomplete replace 
ment of urinary losses This is underscored by the slight 
increases of serum albumin transferrin and IgG that we noted 
1 hese small increases of scrum protein concentrations cannot 
explain the observed changes in proteinuria in view of the 
marked increases in the fractional excretion of albumin IgG 
and transferrin Our study therefore convincingly demonstrates 
that prednisolone acutely increases proteinuria in palients with 
a nephrotic syndrome In the rat a glucocorticoid induced 
increase of protein excretion is also found [7 8) l ime relations 
differ however since we noted an increased protein excretion 
rate as soon as three hours alter administration of prednisolone. 
whereas in rats an increased protein excretion rate is not found 
before eight hours alter administration of the drug 
Several factors could be responsible tor the observed rise m 
protein excretion rate alterations in renal hemodynamics 
changes m tubular protein reabsorption or changes in the 
permselective characteristics of Ihe glomerular basement mem 
branc [10] Chronic administration of corticosteroids increases 
GI R in animals and man [I I-I5J In man this is most likely the 
result of corticosteroid induced increases of plasma and extra 
cellular volume [13] Observations on the acute renal hemody­
namic effects of corticosteroid administration in man are less 
straightforward Although most authors agree that in human 
individuals with normal adrenal lunction no consistent changes 
in GFR or FRPF occur within the first hours after administra­
tion ol corticosteroids [16-19] occasionally increases as well as 
decreases of both GFR and ERPb have been noted [20 21] In 
our patients the increases of prolcm excretion were not accom­
panied by significant changes in Gl R and ERPI Furthermore, 
in the few patients who showed an increase of ERPF or GFR at 
the end of the experiment these changes were always preceded 
by the increases of proteinuria Taken together this makes a 
major role for renal hemodynamics in the proteinuric effect of 
prednisolone less likely However since in human studies only 
information can be obtained on overall renal function an effect 
through redistnbution of renal blood flow cannot be completely 
excluded 
Corticosteroids interfere with proximal tubular transport of 
water and electrolytes as well as of amino acids [15 19,22,23] 
We have used urinary excretion of ßi-microglobulm an anionic 
low molecular weight protein (MW II 600) as a marker of 
tubular protein reabsorption |24 25] Under normal circum-
stances up to 99% of the filtered /}>M is reabsorbed by the 
proximal tubules Tubular reabsorption of albumin is less 
73 
Wetzeis ei at Acute proteinuric effects of prednisolone 
Table 2. Prednisolone induced change;, in ur inary excrel ion o f total p r o l a n a lbumin transferr in IgO and /Э-. microglobul in 
Time 
mm 
-90 to -4 ' î 
- 4 5 to 0 
Oto 60 
60 to 120 
120 10 180 
180 to 240 
240 to 100 
Total 
protein 
5 18 l 0 65 
4 60 ± 0 44 
4 40 + 0 48 
5 55 ± 0 51 
7 00 » 0 »0h 
8 21 î 0 99'· 
9 09 * 0 99h 
Albumin 
4 48 ± 0 53 
4 20 * 0 46 
4 00 ± 0 37 
4 68 * 0 52 
6 08 ± 0 63" 
7 16 * 0 92'' 
8 21 ± 0 SS1· 
Urinary excretion тцітт 
Transfemn 
0 34 ± 0 06 
0 31 ± 0 06 
0 30 ± 0 06 
0 36 ± 0 07 
о 50 ± о mb 
0 48 ± 0 10" 
0 65 ± 0 l l " 
IgC 
0 13 ± 0 03 
0 12 * 0 03 
0 11 ± 0 03 
0 15 ± 004 
0 23 ± 0 07" 
0 31 ± 0 \y 
0 29 ± 0 07" 
/3,M x 10' 
1 94 ± 1 21 
1 92 ± 1 22 
1 43 ± 0 94 
1 68 ± 1 00 
2 10 ± 1 36 
2 08 ± 1 25 
1 77 ± 0 81 
All values are given as mean ± SCM Prednisolone was administrated at time -
" Ρ < 0 05 and b Ρ < 0 01 compared with mean baseline values 
0 mm Baseline values were obtained from -90 mm till 0 mm 
£ 0 8 
E 
E 0 6 • 
β) 
'M 
я 0 ' 
0 2 
Omm 300min Omin 300min 
Time mm 
Fig. 3. Acule effet Is of prednisolone on urinary excretion rales of 
albumin, transferrin, IgO and ß^mu roglobulin (ß2M) Values obtained 
at the start (0 mm) and in the last hour (300 mm) of the expenment are 
shown for the individual patients 
efficient After blockade of tubular protein reabsorption the 
relative increase of urinary ftM excretion exceeds the relative 
increase of urinary albumin excretion severalfold [26] This also 
explains the increased ratio of urinary ftM/unnary albumin 
found in patients with tubular interstitial disease [24] In our 
patients we observed no change in mean unnary ftM excretion 
Individual responses varied, a decrease being found in two 
100 200 300 
Д U IgG % 
Fig. 4. Correlation of the increase of urinary transferrin excretion (A 
Ufr) vuth the increase of urinary IgG excretion f Δ UIgC) For 
companson the line of identity is shown 
patients, an increase in the other six patients Percentual 
increase of unnary ftM excretion was always less then the 
increase of unnary IgG excretion, and in all but one patient less 
then the increase of unnary albumin excretion This is reflected 
by a significant decrease of the ratio unnary ftM excretion/ 
unnary albumin excretion, which, as indicated above, argues 
against a blockade of tubular protein reabsorption Further­
more, in the case of a defect in tubular protein transport 
proteinuna hardly ever exceeds 2 g/24 hr, equalling 1 5 to 2 
mg/min [27] In most of our patients the increase in protein 
excretion rate was considerably greater, which provides further 
evidence that the proteinuric effects of prednisolone are not 
mediated by a decrease in tubular protein reabsorption 
With the necessary precautions in mind we conclude that the 
proteinuric effects of prednisolone cannot be explained by 
changes m renal hemodynamics or tubular protein reabsorp-
tion, and thus must result from a change in glomerular permse-
lectivity characteristics In rat studies the same conclusions 
were reached [7, 8] Although corticosteroids influence GFR in 
rats, the increase in proteinuna occumng 8 to 34 hours after 
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administration of the drugs was not accompanied by increases 
in GFR or lyso¿yme excretion 
In recent years much has been learned about the permeability 
characteristics of the glomerular capillary wall [28] It has 
become evident that the transport of macromolecules through 
the glomerular filter is determined not only by molecular size 
and configuration (size-selectivity) but also to an important 
degree by molecular charge (charge selectivity) The negatively 
charged glomerular basement membrane impairs filtration of 
anionic proteins (such as albumin) Selective loss of glomerular 
basement membrane charges would result in a preferential loss 
of albumin We have studied the urinary excretion of proteins 
with different charge and molecular size such as albumin 
transfemn, and IgO The increases of unnary excretion of these 
proteins were comparable, thus favoring a predominant change 
in glomerular size-selectivity 
It is difficult to denve from data reported in the literature how 
corticosteroids could change glomerular permsclcctivity Since 
adrenalectomy impairs the proteinuric effects of renin and 
norepinephrine in rats, it is assumed that corticosteroids have a 
permissive action on generating this proteinuria [29 30] 
Corticosteroids increase plasma renin activity [IIJ In the light 
of these observations it is tempting to speculate that changes in 
the renin angiotensin system contribute to the proteinuric ef-
fects that w c have observed Since we did not measure plasma 
renin activity or angiotensin II in our patients we cannot deter-
mine their influence on the proteinuric cflcct of prednisolone 
However, in view of the homogeneous response in our patient 
group it would have been difficult to relate changes in protein-
uria to basal levels of renin or angiotensin II Furthermore, 
angiotensin II increases proteinuria mainly by causing vasocon-
striction of the efferent arteriole, leading to an increased glo-
merular capillary pressure which is reflected in an increased 
filtration fraction [29] Recently it was suggested that the pro-
teinuria could be the result of binding of the canonic angiotensin 
II to the GBM and (he subsequent decrease o f O B M negative 
charge [30] The complete absence of changes in FF in our 
study and the absence of a predominant increase of albumin 
excretion indicate that the nature of the proteinuria after ad-
ministration of prednisolone is quite different making a contn-
bution of the renin-angiotensin system less likely 
In our study population the response to prednisolone was 
quite homogeneous an increased proteinuria occurring in all 
patients However, we only studied patients with minimal 
change disease or membranous glomerulonephritis, and ne-
phrotic range proteinuria Therefore one should be careful to 
apply conclusions drawn from our study to patients with renal 
disease and proteinuria from other causes In fact, from an 
ongoing study we have indications that patients with a prolifer-
ative glomerulonephritis do not respond to corticosteroids in a 
similar way bp to this moment the observed effects do not 
seem to have any relation with therapeutic outcome However, 
it is important to realize that during alternate day prednisone 
therapy transient changes in proiemuna can occur, which do 
not reflect therapeutic failure or success 
In conclusion prednisolone can acutely increase proteinuria 
in patients with nephrotic syndrome The absence of changes in 
renal hemodynamics and renal tubular protein reabsorption 
suggest that this effect is caused by changes in glomerular 
permselectivity How the changes in glomerular permselec-
tivity are effectuated remains to be determined 
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CHAPTER Vili 
DECREASES OF PROTEINURIA DURING ALTERNATE-DAY PREDNISONE 
THERAPY IN PATIENTS WITH MEMBRANOUS GLOMERULONEPHRITIS 
J.P.M. Wetzels, A.J. Hoitsma, R.A.P. Koene 
Submitted 
ABSTRACT. 
Treatment of patients with membranous glomerulonephritis [MG] 
with high-dose prednisone on alternate days results in a 
decreased protein excretion rate on non-prednisone days, which 
is not related to any therapeutic effect of prednisone. We have 
studied this phenomenon in more detail in 14 patients [11 M, 
3F] with MG. Mean age [±SD] of the patients was 47±14 years, 
mean endogenous creatinine clearance 94±35 ml/min, and median 
proteinuria 8.8 g/24h [range 5.0-30.0 g/24h]. Glomerular 
filtration rate [GFR, inulin clearance] , effective renal plasma 
flow [ERPF, PAH clearance], and proteinuria were measured on a 
control day [C], and six days after start of alternate-day 
prednisone treatment, on the third non-prednisone day [NP3, 24-
28 hours after the last dose of prednisone]. Proteinuria 
decreased from 6.1 mg/min [3.2-9.8 mg/min] [C] to 2.5 mg/min 
[1.0-7.7 mg/min] at NP3 [median, interquartile range; p<0.01] 
The percentual decrease averaged 45±8%. The decrease of 
proteinuria was correlated with baseline GFR [r=0.75;p<0.01]. 
GFR and ERPF did not change significantly, but filtration 
fraction decreased significantly from 14.5 ± 0.8% [C] to 13.5 ± 
0.9% [NP3; p<0.05]. In 12 patients we measured urinary 
excretion rates of albumin, IgG, transferrin, and /32-
microglobulin. Urinary excretion of all these proteins decrea-
sed significantly, by -39 ± 9%, -60 ± 5%, -50 ± 9%, and -24 ± 
10% respectively. The selectivity index of the proteinuria was 
not different on the study days. We conclude that proteinuria 
is decreased on NP days in patients with MG treated with 
alternate-day steroids. In view of the known permissive effect 
of corticosteroids on proteinuria, this decrease of proteinuria 
might be related to a depressed endogenous Cortisol production 
on NP3 [serum Cortisol C: 0.27 ± 0.04 mmol/1, NP3: 0.10 ± 0.02 
mmol/1; p<0.01]. Mechanisms which are probably involved in this 
decrease of proteinuria are a decrease of intraglomerular 
capillary pressure, and/or a change in glomerular permselec-
tivity characteristics. 
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INTRODUCTION. 
Glucocorticoid treatment is regularly used in patients with a 
nephrotic syndrome caused by membranous glomerulonephritis [1]. 
While treating these patients with high dose prednisone on 
alternate days, we observed a typical fluctuating pattern of 
proteinuria, due to an increased proteinuria on prednisone-days 
and a decrease on non-prednisone days [2,3]. We subsequently 
demonstrated that intravenously administered prednisolone 
increased proteinuria in these patients, thus confirming 
earlier observations of a corticosteroid-induced increase of 
proteinuria [4,5]. The increased proteinuria could not be 
explained by changes in renal hemodynamics or tubular protein 
reabsorption, suggesting that prednisolone increases glomerular 
permeability to proteins [4]. A recent study from Japan 
confirmed these observations [6]. By using fractional clearan-
ces of dextran these investigators demonstrated differences in 
glomerular permeability on prednisone and non-prednisone days. 
Although the observed fluctuations in proteinuria during 
alternate day prednisone therapy may solely be the result of an 
increased proteinuria on prednisone days, it cannot be excluded 
that in addition proteinuria becomes reduced on the non-
prednisone day. We have prospectively studied this possibility 
in detail in patients with membranous glomerulonephritis, who 
were treated with high-dose alternate-day prednisone. The 
results demonstrate that proteinuria is decreased on non-
prednisone days. This decrease of proteinuria might be related 
to a decreased endogenous Cortisol production on non-prednisone 
days, which would be compatible with the known permissive 
effects of corticosteroids on proteinuria in animals [7]. 
PATIENTS AND METHODS. 
We studied 14 patients with a nephrotic syndrome caused by 
biopsy-proven membranous glomerulonephritis. Mean age [± SD] of 
the patients was 47 [± 14] years, mean endogenous creatinine 
clearance [ECC], as calculated from serum creatinine and 24h 
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urinary creatinine excretion, 94 ± 35 ml/min. Three patients 
were treated for hypertension. Pertinent data of the individual 
patients are given in Table I. In all but one patient membra­
nous glomerulonephritis was considered idiopathic. In one 
patient [no.3] the nephrotic syndrome was related to peni­
cillamine treatment for active rheumatoid arthritis. 
All but one patient were admitted to the hospital before start 
of prednisone treatment. For the whole group of patients sodium 
intake ranged from 50 to 200 mmol/day, but it was kept constant 
in the individual patient. A substantial part of this sodium 
was supplied by sodium bicarbonate which was given in a dose of 
3-6 g/day, in order to keep urinary pH above 6.0 [which was 
necessary for correct measurement of /32-microglobulin; vide 
infra]. Patients were treated with prednisone orally in a dose 
of 125 mg [body weight <80 kg] or 150 mg [body weight >80 kg] 
on alternate days. 
Detailed studies of renal function and proteinuria were done on 
a control day [C, day before start of prednisone treatment] and 
Table I. Patient characteristics. 
ients 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
> Sex 
F 
M 
M 
F 
M 
M 
M 
F 
M 
M 
M 
M 
M 
M 
Age 
(years) 
47 
37 
70 
38 
54 
58 
59 
52 
41 
27 
40 
68 
24 
42 
Proteinuria 
(g/24h) 
11.6 
9.8 
8.9 
5.0 
5.0 
5.5 
5.8 
12.4 
30.0 
6.2 
8.7 
12.0 
5.2 
15.9 
ECC 
(ml/min) 
74 
90 
97 
150 
81 
90 
113 
51 
69 
86 
141 
23 
121 
134 
Therapy 
Fu, С 
Fu 
H,I 
M,D,Dil 
Μ,E 
FU 
FU 
Fu 
Fu 
A 
Abbreviations: ECC=endogenous creatinine clearance. Fu=furose-
mide,C=captopril/I=indomethacin,H=hydroxychloroquine,M=metopro-
lol,D=dipyridamol,Dil=diltiazem,E=endralazine, A=atenolol. 
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six days after start of treatment, i.e. on the third non-
prednisone day [NP3]. All studies were done between 9.00 a.m. 
and 1.00 p.m., to exclude any influence from diurnal rhythms. 
The patients took a light breakfast on the study day. A 
sufficient diuresis was established by an oral water load of 
500-1000 ml. Thereafter, we tried to maintain diuresis by 
giving water orally. Glomerular filtration rate [GFR] and 
effective renal plasma flow [ERPF] were measured using a 
continuous infusion technique. Renal clearances of inulin 
[InutestR - Laevosan GMBH, Linz, Austria] and para-amino-
hippurate [PAH] were used as markers of GFR and ERPF, respec-
tively. After an equilibration period of 90 min, two or three 
urine samples were collected at regular intervals [30-60 min] 
for determination of creatinine, inulin, PAH, sodium, total 
protein, albumin, transferrin, IgG and /32-microglobulin [/32M] . 
Urine was collected by spontaneous voiding. At the mid-point of 
the urine collection periods, blood was drawn for determina-
tions of inulin, PAH, creatinine, sodium, albumin, IgG, 
transferrin, /32M, total protein, and hematocrit. In addition 
blood samples were drawn at the start of the experiments to 
determine inulin and PAH "blanks". At this time a blood sample 
was drawn for determination of Cortisol. 
Sodium, creatinine, inulin and PAH in urine and serum were 
measured using standard semi-automated techniques. Urinary 
total protein was measured using the biuret method. Plasma 
Cortisol was measured using a specific radioimmunoassay. 
Albumin, transferrin and IgG in urine and serum were measured 
by immunonephelometry using specific antibodies raised in 
rabbits. Serum and urinary /?2M were measured using a commer-
cially available radioimmunoassay [Pharmacia]. In one patient, 
no serum PAH values could be determined due to technical 
difficulties. In two patients no urine samples for determina-
tions of albumin, IgG, transferrin, and /92M were collected. 
The percentual decrease of proteinuria was defined as the 
difference of the protein excretion on the control day and NP3, 
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divided by proteinuria on the control day. Filtration fraction 
[FF] was defined as [GFR/ERPF]*100%. Renal blood flow was 
calculated as ERPF/[1-Ht]. The fractional excretion [FE] of a 
substance was defined as the renal clearance of that substance 
divided by the GFR and expressed as a percentage. 
Values are given as means [+SEM], When a non-normal distribu­
tion applied medians [interquartile range [IQR] ] are given. 
For statistical analysis Student's t-test and Wilcoxon's sign 
rank test were used when appropriate. Linear regression was 
calculated using Spearman's correlation coefficient. A Ρ value 
of less than 0.05 was considered significant. 
The study protocol was approved by the Hospital Ethics Com­
mittee. All patients gave informed consent. 
RESULTS. 
Alternate-day prednisone treatment caused a suppression of 
endogenous Cortisol production on the non-prednisone days, 
Cortisol levels averaging 0.27 ± 0.04 mmol/1 on the control day 
[C] and 0.10 ± 0.02 mmol/1 on the third non-prednisone day 
[NP3; p<0.01]. Values of serum creatinine, serum sodium, and 
serum total protein were not different on the study days. How­
ever, hematocrit decreased slightly but significantly by on 
average -0.02+0.01 1/1 [C:0.40 ± 0.02 1/1; NP3:0.38 ± 0.02 1/1; 
p<0.05]. 
After start of treatment we observed the typical fluctuating 
pattern of proteinuria. The changes in protein excretion could 
largely be explained by a decreased proteinuria on non-pred­
nisone days. Urinary total protein excretion decreased from 6.1 
mg/min [IQR 3.2-9.8 mg/min] at baseline to 2.5 mg/min [IQR 1.Ο­
ν.7 mg/min] on NP3 [p<0.01]. Values in the individual patients 
are shown in Fig. 1. Proteinuria decreased in all but one 
patient [no.8], percentual decrease averaging -45 ± 8% [range 
+20% to -94%]. 
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22 
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А I 
control 
non-
predmsone 
Figure 1. Proteinuria on the control day and on the third 
non-prednisone day. Data of the individual patients 
and medians [interquartile range] are shown. 
Table II.Renal function parameters. 
Urine flow [ml/min] 
U V N a [дтоі/тіп] 
ECC [ml/min] 
GFR [ml/min] 
ERPF [ml/min] 
RBF [ml/min] 
FF [ %] 
Control 
5.7 ± 
102 ± 
112 ± 
75 ± 
517 ± 
893 ± 
14.5 ± 
0.9 
16 
14 
10 
71 
122 
0.8 
Non-
prednisone 
6.5 ± 
100 ± 
103 ± 
70 ± 
516 ± 
861 ± 
13.5 ± 
0.8 
17 
11 
8 
66 
121 
0.9 
P-value 
ns 
ns 
p=0.08 
p=0.10 
ns 
ns 
p<0.05 
Abbreviations: и ^
а
=игіпагу sodium excretion. ECC=endogenous 
creatinine clearance. GFR=glomerular filtration rate. ERPF= 
effective renal plasma flow. RBF=renal blood flow. FF=filtra-
tion fraction. 
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Concomitant values of renal function parameters are given in 
Table II. Urinary flow rate and urinary sodium excretion were 
not different. Although ECC, GFR, ERPF, and RBF did not change 
significantly, filtration fraction fell slightly but sig­
nificantly by -7 ± 2% [p<0.05]. 
The percentual decrease of proteinuria was significantly cor­
related with baseline GFR [Fig. 2; r=0.75,p<0.01], indicating 
that the decrease of proteinuria was most prominent in patients 
with well-preserved renal function. 
The decrease of urinary protein excretion on NP3 was not 
restricted to a specific protein. Urinary excretion of all 
proteins that we measured decreased significantly [Table III]. 
0) 
О 
i _ 
CL 
20-
0-
-20. 
-да 
E -60. 
-80. 
-lOOJ 
50 1Q0 GFR(ml/min) 
1 
r=075 
p<0 01 
Figure 2. Relationship between the percentual decrease of 
proteinuria and baseline glomerular filtration rate 
[GFR]. 
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Table I I I . Serum concentrations and urinary excretie»! rates of albumin, 
IgG, transferrin, and /?2-iidcroglobulin on the control day and the third 
non-prednisone day. 
Serum: 
albumin [g/1] 
IgG [g/l] 
t r a n s f e r r i n [ g / l ] 
02-nücrOglcbulin [mg/l] 
Urinary e x c r e t i o n : 
albumin [mg/min] 
IgG [mg/min] 
t r a n s f e r r i n [mg/min] 
/^ -microglobul in 
[μς/πιϊη] 
F r a c t i o n a l e x c r e t i o n : 
albumin [%] 
IgG [%] 
t r a n s f e r r i n [%] 
j92-microylQbilin [%] 
S e l e c t i v i t y irriex 
Control 
20.4 ± 2 . 1 
3.9 [2.9-7.0] 
1.9 ± 0.2 
2.7 ± 0.3 
3.5 [2.1-6.5] 
0.08 [0.05-0.34] 
0.33 [0.16-0.62] 
0.32 [0.15-6.51] 
0.28 [0.10-0.70] 
0.36 [0.08-1.2 ] 
0.27 [0.07-0.69] 
0.17 [0.10-5.0 ] 
0.16 [0.10-0.27] 
Non-
prednisone 
21.2 ± 1.9 
3.4 [2.5-6.9] 
2.0 ± 0.2 
2.4 ± 0.3 
2 . 1 [1 .1-4.4] 
0.04 [0.01-0.16] 
0.18 [0.03-0.32] 
0.26 [0.14-3.56] 
0.17 [0.06-0.47] 
0.12 [0.04-0.85] 
0.16 [0.02-0.46] 
0.15 [0.10-3.22] 
0.16 [0.10-0.27] 
P-value 
n s 
p<0.01 
ns 
p<0.02 
p<0.01 
p<0.01 
p<0.01 
p<0.01 
p<0.01 
p<0.01 
p<0.01 
p<0.05 
ns 
Values are given as means [±SEM] or median [IQR]. 
The percentual decreases of the ur inary excret ion of these 
prote ins are depicted in Fig. 3. The average decrease of IgG 
excret ion [-60 ± 5%] exceeded the decrease of albumin excret ion 
[-39 ± 9%; p=0.06], and of β2Κ [-24 ± 10%; p<0.01]. However, 
these di f ferences are t o some extent explained by the d i f fe rent 
changes in serum concentrat ions of the r e s p e c t i v e prote ins 
[Table I I I ] , IgG and /32M being s i g n i f i c a n t l y lower on NP3. If 
the changes in GFR and serum concentrat ions are taken into 
account by c a l c u l a t i n g f rac t iona l e x c r e t i o n s , percentual 
decreases of albumin, t r a n s f e r r i n , and IgG excret ion are 
comparable [Table I I I ] . As a consequence s e l e c t i v i t y of 
p r o t e i n u r i a remained unchanged. Fract iona l excret ion of /32M 
[-12±10%] was reduced l e s s than f r a c t i o n a l excre t ions of IgG 
[-52±6%;p<0.01], t r a n s f e r r i n [-52±7%; p<0.02], and albumin [-40 
±8%;p=0.06]. 
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DISCUSSION 
Our study demonstrates that during treatment of patients with 
high-dose prednisone on alternate days, proteinuria on non-
prednisone days is decreased when compared to pre-treatment 
values. Our study extends recent observations on the fluctua­
ting pattern of proteinuria during alternate-day prednisone 
therapy [3,6]. When we calculated the ratio of protein excre­
tion rates on prednisone and non-prednisone days from these 
previous studies we found that proteinuria was a factor 1.5-
2.0 higher on prednisone days [3,6]. In the present study the 
decrease of proteinuria on a non-prednisone day was compared 
with pre-treatment values and was found to average 45%, i.e. a 
ratio of 1.6. Thus, the observed changes in proteinuria during 
alternate-day prednisone therapy are predominantly determined 
by a decreased proteinuria on non-prednisone days, and to a 
lesser degree by a corticosteroid-induced increase of proteinu­
ria on prednisone days. 
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Although our study was not controlled, it is unlikely that the 
decreases of proteinuria on non-prednisone days occurred spon-
taneously. In hospitalized patients only slight variations of 
proteinuria, occurring at random, are found [8]. Furthermore, 
although circadian rhythms of proteinuria exist, our observa-
tions would require the existence of a 48h-rhythm, and in 
detailed studies on the rhythmicity of proteinuria such a 
rhythm was not noted [9]. It is also unlikely that the decrea-
ses of proteinuria on non-prednisone days is explained by an 
instantaneous therapeutic effect of prednisone. First, treat-
ment related reductions of proteinuria, if at all, are seldom 
observed in the first months after treatment start [10]. 
Secondly, we observed no further diminution of proteinuria on 
prednisone or non-prednisone days in patients studied during 
longer periods [3]. Thirdly, in most of the patients of the 
present study no sustained decrease of proteinuria was observed 
after the end of treatment. 
Several mechanisms might explain the observed decrease in 
proteinuria: changes in systemic and renal hemodynamics, 
changes in tubular protein reabsorption, or changes in the 
permselectivity characteristics of the glomerular basement 
membrane [11]. Although we did not systematically measure blood 
pressure during the renal function measurements, we observed no 
difference in blood pressure measurements performed in our 
patients on prednisone and non-prednisone days. Kumagai et al. 
also did not observe differences in blood pressure between 
prednisone and non-prednisone days [6]. From this we conclude 
that changes in systemic hemodynamics probably do not con-
tribute to the observed effects of alternate day prednisone 
therapy. 
With regard to renal hemodynamics, we did not observe major 
alterations in glomerular filtration rate or renal blood flow. 
Filtration fraction decreased significantly, however. These 
results are in full agreement with the Japanese study, demon-
strating unchanged GFR and ERPF, but a considerable decrease of 
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FF on non-prednisone days as compared to prednisone days [6] . 
This decrease of filtration fraction probably indicates a 
decrease in glomerular capillary pressure, which could at least 
partly explain the decrease in proteinuria. The fact that the 
change in filtration fraction is relatively minor [-7%] as 
compared with the change in proteinuria [-45%] would suggest 
that other factors must be involved. However, one should be 
careful to draw such a conclusion, since in human beings 
measurements of renal hemodynamics are not precise enough to 
detect changes in glomerular capillary pressure, especially 
when changes in ultrafiltration coefficient or renal blood flow 
distribution would occur concurrently. 
We have used urinary /32M excretion as a marker of tubular 
protein reabsorption [12]. Under normal circumstances up to 99% 
of filtered /32M is reabsorbed by the proximal tubules. Tubular 
reabsoption of albumin is less efficient. After blockade of 
tubular protein reabsorption the relative increase of urinary 
/32M excretion exceeds the relative increase of urinary albumin 
excretion severalfold [13]. In the present study fractional 
excretion of /32M was altered less during alternate day pred-
nisone therapy, which argues against important changes in 
tubular protein reabsorption. Also the magnitude of the effect 
makes an effect through altered tubular protein reabsorption 
less likely. In case of a defect in tubular protein transport, 
proteinuria hardly ever exceeds 2 g/2 4h, which is taken as 
evidence that tubular transport is limited. Certainly, we 
cannot completely exclude that tubular transport capacity is 
increased in patients with a nephrotic syndrome. In fact, 
recent studies in rabbits have demonstrated that tubular 
transport of albumin is not readily saturable , and has a high 
capacity [14]. 
In recent years it has become evident that the transport of 
macromolecules through the glomerular filter is determined by 
molecular size and configuration [size-selectivity] and by 
molecular charge [charge-selectivity]. We have studied urinary 
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excretions of proteins of different size and charge such as 
albumin, transferrin, and IgG. The decreases of urinary 
excretion of these proteins were comparable, favouring a 
predominant change in glomerular size-selectivity. This again 
is in close agreement with the results of Kumagai et al. who 
studied the fractional clearances of neutral dextrans to detect 
changes in glomerular permeability [6], and observed that the 
fractional clearances of dextran molecules with a molecular 
radius greater than 3.6 nm were significantly lower on the non-
prednisone day. 
Thus, proteinuria is decreased on non-prednisone days during 
alternate day steroid therapy. Our and Kumagai's data suggest 
that the decreased proteinuria is related to a decreased capil-
lary pressure and a decreased glomerular permeability. How 
could alternate-day prednisone therapy influence proteinuria? 
Based on data reported in the literature it is tempting to 
speculate on the role of Cortisol in proteinuria. Adrenalectomy 
reduces the basal proteinuria in normal and spontaneously 
hypertensive rats [15]. Similar reductions of proteinuria are 
seen in male rats after hypophysectomy [16]. Also, proteinuric 
responses to renin, angiotensin II and norepinephrine are 
completely inhibited by adrenalectomy or hypophysectomy 
[7,16,17]. In most studies proteinuria or proteinuric responses 
are normalized after administration of glucocorticoids but not 
mineralocorticoids [7,15-17]. Based on these studies glucocor-
ticoids are thought to exert a permissive action on proteinu-
ria. The exact mechanism of this effect is debated. In most 
studies the importance of hemodynamic factors is stressed, 
adrenalectomized rats demonstrating a low GFR and ERPF. If 
administration of corticosteroids is followed by normalisation 
of GFR, proteinuria is restored to normal [17]. However, Bauman 
did not observe major differences in renal hemodynamics between 
adrenalectomized rats treated with dexamethasone or aldosterone 
[7]. Since dexamethasone but not aldosterone restored proteinu-
ria to normal he argued that corticosteroids might directly 
alter glomerular permeability. 
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Results of recent studies have stimulated the interest in the 
effects of corticosteroids on proteinuria. In the remnant-
kidney model in the rat, a non-immunological model of progres-
sive renal failure, chronic administration of pharmacological 
doses of methylprednisolone enhanced proteinuria and ac-
celerated the development of glomerular sclerosis [18]. These 
detrimental effects of chronic steroid administration were 
attributed to an increased glomerular capillary pressure. In 
this respect chronic steroid administration closely resembles 
daily high protein feeding [19]. Our findings demonstrate that 
during alternate-day prednisone treatment proteinuria and 
possibly also glomerular capillary pressure are intermittently 
decreased. In view of the fact that intermittent high protein 
feeding has less damaging potential in the above-mentioned rat 
model, it is tempting to speculate that intermittent ad-
ministration of steroids might prove less vulnerable to the 
kidneys than daily administration. Evidence for a role of 
Cortisol production in progressive renal insufficiency in 
humans was put forward in a recent study in patients with renal 
failure [20]. The excretion of 17-hydroxycorticosteroids proved 
a major determinant of the rate of progression. Patients with a 
relatively low production of glucocorticoids showed a slower 
progression rate. This study indicates that steroids at 
physiological levels might influence glomerular damage. Our 
observation that proteinuria is reduced at moderately decreased 
plasma Cortisol levels seems compatible with a role for 
steroids in the process of continuing glomerular damage. 
In conclusion: we have demonstrated a decreased proteinuria on 
non-prednisone days during alternate-day prednisone therapy. 
Suppression of endogenous Cortisol production resulting in a 
decreased glomerular capillary pressure and a decreased 
glomerular permeability may be the primary determinants of this 
effect. Further studies on the effects of corticosteroids on 
proteinuria might open new ways to treatment of proteinuria and 
progressive renal failure. 
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CHAPTER IX 
ANALYSIS OF SHORT-TERM ALTERNATE-DAY PREDNISONE THERAPY IN 
PATIENTS WITH MEMBRANOUS GLOMERULONEPHRITIS 
J.F.M. Wetzels, A.J. Hoitsma, R.A.P. Koene 
ABSTRACT 
We have analysed the effects of treatment with prednisone, 125-
150 mg on alternate days for eight weeks, in 34 patients [28 
male, 6 female] with biopsy-proven idiopathic membranous 
glomerulonephritis. Median duration of disease at the start of 
treatment was two months [range 0-146 months] and follow up 
after start of treatment averaged 52 months [range 12-108 
months]. Thirteen patients [38%] reached a partial remission of 
proteinuria, which was followed by a complete remission in six 
[18%]. After five years 25% of the patients had died or had 
reached end-stage renal disease. Renal function deteriorated in 
none of the women. In contrast, 15 men [54%] developed renal 
insufficiency, nearly all within two years after start of 
treatment. Patients developing renal insufficiency were 
characterized by impaired renal function, higher proteinuria, 
lower protein selectivity, and higher blood pressure at the 
start of the treatment. Retrospectively, an increased urinary 
excretion of the low molecular weight protein /32-microglobulin 
was a good discriminative marker of subsequent deterioration of 
renal function. In conclusion: our results indicate that pred-
nisone treatment according to the abovementioned schedule is of 
doubtful significance in patients with membranous glomerulo-
nephritis. New immunosuppressive treatment regimens might best 
be restricted to male patients in whom prognostic factors point 
to a high likelihood of progressive renal failure. 
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INTRODUCTION 
Membranous glomerulonephritis is the most common cause of the 
nephrotic syndrome in adults [1]. The natural course of 
idiopathic membranous glomerulonephritis is quite variable. In 
the long run about half of the patients reach a complete or 
partial remission of proteinuria, whereas the other half 
develop progressive renal insufficiency [2]. It is debatable, 
whether treatment with corticosteroids or other immunosuppres-
sive drugs can alter the course of the disease [3-5]. In 1979 
the Collaborative Study of the Adult Idiopathic Nephrotic 
Syndrome reported beneficial effects of short-term alternate-
day prednisone treatment [6]. Lately, the efficacy of pred-
nisone treatment has been questioned [7], and more promising 
results were obtained using the immunosuppressive drug chloram-
bucil [8]. Since 1980 we have been treating patients with 
idiopathic membranous glomerulonephritis with alternate-day 
prednisone according to the protocol of the abovementioned 
study [6]. We have analysed the course of disease in these 
patients and have tried to identify factors which could predict 
subsequent development of renal insufficiency. 
PATIENTS AND METHODS 
Since 1980 we have investigated the acute effects of prednisone 
on proteinuria in patients with a nephrotic syndrome [9-11]. In 
these studies 34 patients with a biopsy-proven idiopathic 
membranous glomerulonephritis were included. They were treated 
with prednisone, 125-150 mg on alternate days for eight weeks, 
and were regularly followed thereafter. We have reviewed the 
clinical records of these patients and recorded the relevant 
data. One patient [no 6] was lost to follow-up five years after 
start of treatment. 
In half of the patients detailed measurements of renal function 
were done at the start of treatment. Renal clearances of inulin 
and PAH were used as markers of glomerular filtration rate 
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[GFR] and effective renal plasma flow [ERPF] respectively. At 
the time of these renal function measurements, blood and urine 
samples were drawn for the measurements of albumin, transfer­
rin, IgG, and 02-microglobulin. To keep urinary pH above 6.0, 
which is necessary for correct measurement of urinary /?2-
microglobulin, most patients were pretreated with sodium 
bicarbonate. 
Albumin, transferrin, and IgG were measured by immunonephelome-
try using specific antibodies raised in rabbits. Serum and 
urinary β 2-microglobulin were measured using a commercially 
available radioimmunoassay [Pharmacia]. All other labatory 
parameters were measured using standard semi-automated tech­
niques. Selectivity of proteinuria was calculated as the ratio 
of the clearances of IgG and transferrin. Proteinuria was 
measured in a 24 h urine sample or, if not available, calcu­
lated from the protein/creatinine ratio determined in a random 
urine sample. A complete remission of proteinuria was defined 
as a decrease to less than 0.2 g/24h, a partial remission as a 
decrease to less than 2.0 g/24h. 
Differences between groups were analysed using a non-parametric 
Wilcoxon test. Values are given as means [± SEM] or medians 
[interquartile range] when appropriate. 
RESULTS 
We have studied 34 patients [28M, 6F] with idiopathic membra­
nous glomerulonephritis. The median interval between renal 
biopsy and start of prednisone treatment was 2 months [range 0-
146 months]. In three quarter of patients treatment was started 
within eight months after biopsy. Clinical data at the start of 
treatment are given in table I. In all patients the treatment 
course was completed. The evolution of proteinuria is depicted 
in figure 1. Overall 13 patients [10M, 3F] reached a partial 
remission of proteinuria, which was followed by a complete 
remission in six [18%]. In three patients a complete remission 
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m 
m 
proteinuria <0.2 g/24 h 
proteinuria 0.2-2.0 g/24 h 
proteinuria >2.0 g/24 h 
Figure 1: Evolution of proteinuria before and after the start 
of prednisone treatment [at 0 months]. Patient 
numbers are indicated at the left. Female patients 
are marked with an asterisk. HD=hemodialysis. One 
patient died during follow up [f]. 
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Table I. Clinical data at start of prednisone treatment. 
Men Women 
[n=28] [n=6] 
Age [years] 45 [±3] 39 [±5] 
Blood pressure [mmHg] 
systolic 
diastolic 
Serum creatinine [μιηοΐ/ΐ] 
Serum albumin [g/1] 
Proteinuria [g/24h] 
ECC [ml/min/1.73m2] 
145 
85 
92 
24.7 
7.0 
89 
[±2] 
[±2] 
[81-124] 
[±1.3] 
[5.5-13] 
[82-113] 
156 
87 
89 
25.5 
9.0 
90 
[±8] 
[±3] 
[71-113] 
[±1.5] 
[6.5-15.5] 
[65-121] 
Abbreviation: ECC = endogenous creatinine clearance. Values are 
given as means [±SEM] or medians [interquartile range]. 
was reached within one year after start of treatment. It is 
evident from the figure that most patients have a persistent 
proteinuria of more than 2.0 g/24h. Persistence of an evident 
nephrotic syndrome [i.e proteinuria >3.5 g/24h and serum 
albumin <30 g/1] is rare however, occurring in 9 of 29 patients 
at two years and in only one patient at four years after the 
start of treatment. The course of renal function is depicted in 
figure 2. During follow-up, five patients reached end stage 
renal disease, all within five years after start of treatment, 
and one patient died because of a myocardial infarction. Women 
showed a good prognosis, since in none renal function decrea­
sed. In contrast, deterioration of renal function [i.e serum 
creatinine >130 дтоі/і] developed in 15 of 28 male patients 
[54%]. Twelve of these patients could be identified within two 
years after start of therapy. When comparing patients with 
stable renal function [group I] and those with deteriorating 
renal function [group II], differences are evident [table II]. 
Patients progressing to renal insufficiency are characterized 
by a higher blood pressure, an elevated serum creatinine, more 
proteinuria and a lower selectivity of proteinuria. In the sub­
group of patients in whom more detailed studies of renal func­
tion and proteinuria were done, a similar pattern occurred, 
which was reflected in differences in GFR [78±7 vs 45±7 
ml/min/1.73m2; p<0.01], albuminuria [3.3±0.8 vs 7.1±1.4 mg/min; 
ρ <0.05], serum transferrin [2.4±0.3 vs 1.5+0.2 g/1; ρ <0.05], 
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' J creatinine < 130 μπηοΙ/Ι 
i creatinine 130-450 μιτιοΙ/Ι 
Ι creatinine >450 μπιοΙ/Ι 
Figure 2: Course of renal function as reflected by serum 
creatinine concentration. For explanation see 
figure 1. 
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Table II. Clinical data in men with and without renal insuf­
ficiency during follow-up 
Age [years] 
Blood pressure [mmHg] 
systolic 
diastolic 
Serum creatinine 
[μηοΐ/ΐ] 
ECC [ml/min] 
Serum albumin [g/1] 
Proteinuria [g/24h] 
Selectivity index* 
Group 
[n=13; 
44 
139 
82 
82 
105 
26.8 
6.0 
0.12 
I 
] 
[4] 
[3] 
[2] 
[79-98] 
[84-131] 
[1.6] 
[5.3-7.3-
[0.02] 
Group : 
[n=15: 
45 
150 
89 
118 
81 
22.9 
| 10.2 
0.24 
EI 
] 
[4] 
[3] 
[2] 
[95-150] 
[61-95] 
[1.8] 
[6.7-15.6] 
[0.04] 
P-value 
N.S. 
P<0.05 
P<0.01 
P<0.01 
P<0.01 
N.S. 
P<0.02 
P<0.05 
Abbreviations: ECC=endogenous creatinine clearance. Values are 
given as means [SEM] or medians [interquartile range]. Group I 
represents patients with stable renal function, group II 
patients with renal insufficiency. 
* Values recorded in 10 and 9 patients respectively. 
and serum /32-microglobulin [1.9+0.1 vs 3.3±0.4 mg/1]. In ad­
dition group II patients nearly all had increased urinary ex­
cretion of 02-microglobulin [group I: 147ng/min [IQR 104-255] 
group II: 2806 ng/min [IQR 760-12209]; p<0.01]. Most of these 
differences can be attributed to the initially already impaired 
renal function in group II patients. When we analysed patients 
with an initial endogenous creatinine clearance [calculated 
from serum creatinine and 24h creatinine excretion] above 80 
ml/min/1.73m2 , urinary /32-m:'-cro9lobul;'-n excretion was most 
discriminative in predicting subsequent renal function 
deterioration [Fig.3]. In all but two patients with a serum 
creatinine above 130 μιηοΐ/ΐ, renal function declined 
progressively. In the two patients without progression an 
improvement of renal function was observed after treatment with 
chlorambucil and prednisone as described previously [12]. Side 
effects of treatment were infrequent:steroid diabetes [n=l], 
sinusitis [n=l], erysipelas [n=l], and perforated sigmoid in a 
patient with known diverticular disease. 
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Figure 3 : Comparison of laboratory parameters in patients 
with initial ECC higher than 80 ml/min/1.73m2. 
Patients are divided according to course of renal 
function. Group I represents patients with stable 
renal function, group II patients with renal 
insufficiency during follow-up. ECC=endogenous 
creatinine clearance; GFR=glomerular filtration 
rate (inulin clearance); Scr=serum creatinine; 
U/32M=urinary 02-microglobulin excretion. 
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DISCUSSION 
Idiopathic membranous glomerulonephritis follows a variable, 
rather indolent course [reviewed in chapter II]. Up to this 
moment no consensus exists regarding the treatment of these 
patients [3-5]. In 1979, the results of the first controlled 
trial, involving a sufficient number of patients, were reported 
[6]. Patients were treated with alternate-day prednisone for 
eight weeks. Results of the trial were promising, especially 
with respect to the prevention of deterioration of renal 
function. Recently, controlled trials published in full [7] or 
in abstract form [13] could not confirm the beneficial effects 
of prednisone monotherapy in idiopathic membranous glomerulo-
nephritis. However, combined treatment with prednisone and 
chlorambucil proved very effective [8], even in patients with 
deteriorating renal function [14, and reviewed in chapter II 
and X] . It is, however, not clear whether this difference was 
caused by the addition of chlorambucil to the treatment or by 
the fact that the course was started with three intravenous 
pulses of high dose methylprednisolone. 
In view of the recent discussion regarding prednisone treatment 
in patients with idiopathic membranous glomerulonephritis, we 
have analysed the course of the disease in our patients who had 
been treated with short-term alternate-day prednisone. The 
clinical characteristics of our patient group recorded at the 
start of prednisone treatment fit well with those reported in 
the literature, patients being predominantly male, 85% having a 
nephrotic syndrome, and 20% an impaired renal function at the 
start of treatment. 
Our results confirm that membranous glomerulonephritis has a 
favourable course in women [15, and chapter II]. Male patients 
do clearly less well: in more than half of these patients renal 
function deteriorated during follow-up. In agreement with data 
in the literature most of the patients with deteriorating renal 
function could be identified within two years after treatment 
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start. 
Overall 38% of our patients reached a partial or complete 
remission of proteinuria, whereas 45% developed renal insuffi-
ciency. These results are comparable with the results reported 
in untreated patients, where the reported frequency of partial 
and complete remission varies from 18-65%, and the percentage 
of patients with evidence of renal function deterioration 
ranges from 19-52% [chapter II]. Certainly, since our study is 
uncontrolled our data do not permit to exclude any beneficial 
effect of short-term prednisone treatment. However, in any 
event the results indicate that a large number of patients do 
not benefit from this treatment regimen. 
Some clinical characteristics can apparently help to identify 
patients who are at risk for developing renal insufficiency at 
an early stage. These factors are: male sex, severe proteinu-
ria, non-selective proteinuria, and impairment of renal 
function. In addition, urinary excretion of the low molecular 
weight protein /J2~mi-cro9l0fc)ulin may be a useful discriminative 
marker in this respect. 
In a recent controlled study a combination of chlorambucil and 
prednisone was very effective in patients with idiopathic 
membranous glomerulonephritis [8]. A similar treatment regimen 
was also effective in patients with deteriorating renal 
function [14]. Using a similar regimen we were able to reverse 
the decrease of renal function in two patients [12]. If these 
results are confirmed, such an agressive treatment could be 
reserved for patients at high risk of developing progressive 
renal failure, and treatment could be safely withheld from 
patients who probably will never develop renal failure. 
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CHAPTER Χ 
CHLORAMBUCIL IN STEROID-RESISTANT MEMBRANOUS GLOMERULONEPHRITIS 
J.F.M. Wetzels, A.J. Hoitsma, K.J.M. Assmann, R.A.P. Koene and 
the Membranous Glomerulonephritis Study Group 
Published in part as a letter in The Lancet 1989; I: 211. 
ABSTRACT 
We have studied the effects of chlorambucil in eight patients 
with idiopathic membranous glomerulonephritis, who had been 
treated with high doses of prednisone for at least three 
months, but showed persisting nephrotic syndrome and/or 
deteriorating renal function. All were men and their mean age 
was 48 years [range 17-64 y]. Chlorambucil was given in a dose 
of 0.2 mg/kg/day in three periods of four weeks, separated by 
two week intervals during which the patients were treated with 
prednisone in a dose of 125 mg on alternate days. All patients 
were followed for at least 24 months. For the whole group of 
patients the rise of mean serum creatinine was interrupted, 
proteinuria decreased, and serum albumin increased after start 
of the chlorambucil treatment. However, these beneficial 
effects were most prominent at six months and not sustained in 
all patients. In two patients who entered the study with stable 
renal function, this remained unchanged. Six patients entered 
the study with evidence of deteriorating renal function. In 
five renal function improved or stabilized, but this response 
was sustained in only three. Side effects of chlorambucil 
treatment were anorexia and nausea [n=3], itching [n=2], and 
exanthema [n=l]. Furthermore, in all but one patient the dosage 
of chlorambucil had to be reduced because of leukocytopenia and 
thrombocytopenia. We conclude that chlorambucil may have 
beneficial effects in some patients with membranous glomerulo-
nephritis who did not respond to prior treatment with cortico-
steroids. 
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INTRODUCTION 
Membranous glomerulonephritis is the most common glomerular 
disease underlying the nephrotic syndrome in adults [1]. The 
clinical course of the disease is rather unpredictable, 
complete remissions occurring spontaneously in about a quarter 
of untreated patients, whereas up to 50% show a steady decline 
of renal function [2,3]. Whether drug therapy can alter the 
course of the disease is still a matter of controversy [4-6]. 
Short-term high-dose alternate-day prednisone therapy was used 
in a controlled, prospective study conducted more than 10 years 
ago and seemed effective in preventing progressive renal 
failure [7]. These results have been questioned however, and 
could not be confirmed in more recent trials [8,9]. In a recent 
study in patients with well-preserved renal function promising 
results were obtained using a six month course of alternating 
monthly cycles of chlorambucil and prednisone [10]. Up to 75% 
of treated patients reached a complete or partial remission of 
proteinuria, and only a minority showed evidence of renal 
function deterioration. We have studied the effect of chloram-
bucil in patients with membranous glomerulonephritis who had 
been treated with prednisone, but who showed persisting 
nephrotic syndrome and/or a decline of renal function. 
PATIENTS AND METHODS 
We have studied eight men with biopsy-proven idiopathic 
membranous glomerulonephritis. All had been treated with high-
dose prednisone for at least three months, but showed persis-
tent nephrotic syndrome and/or deteriorating renal function. 
Clinical data of the patients are given in Tables I and II. 
Patients were treated with chlorambucil and prednisone. In view 
of the earlier exposure to steroids we slightly modified the 
treatment regimen of Ponticelli [10]. In particular we omitted 
the three initial pulses of one gram of methylprednisolone and 
we reduced the prednisone treatment periods from four to two 
weeks. Chlorambucil was prescribed in a dose of 0.2 mg/kg/day 
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Table I. Patient characteristics at the start of chlorambucil treatment. 
patient 
no. 
1 
2 
3 
4 
5 
6 
7 
8 
Age 
[yr] 
53 
45 
34 
64 
17 
62 
57 
50 
Serum creatinine 
[щюі/і] 
80 
176 
136 
161 
511 
175 
126 
262 
Proteinuria 
[g/24h] 
8.6 
8.3 
6.2 
10.6 
3.2 
22.3 
12.4 
9.1 
Blood pressure 
[mmHg] 
120/ 70 
130/ 85 
115/ 85 
160/100 
180/115 
180/ 90 
158/ 70 
170/105 
Medication 
Ac 
ΑΙ,Ρ,Ε,Τ 
-
Ald,F,R 
Α,Η,Τ 
Ac,F 
-
F,M 
Abbreviations: AF=acébutolol, Ас=асепоссшіаго1, Al=allopurinol, Ald=4ildac-
tone, E=endralazine, F=furOseniide, H=hydralazine, M=inetoprolol, P=pindolol, 
R=ranitidine, T=thiazide. 
Table II. Patient characteristics [continued]. 
no. 
1 
2 
3 
4 
5 
6 
7 
8 
II-III 
II 
I 
II 
II-III 
II 
I 
I-II 
Renal biopsy findings 
Grade Tubulointerstitial 
lesions 
Duration Interval to Follcw up 
of previous start of [months] 
treatment chlorambucil 
[months] [months] 
+ 
+ 
3 
3 
31 
3 
3 
3 
3 
12 
4 
7 
1 
5 
21 
1 
32 
15 
24 
36 
36 
24 
36 
36 
30 
36 
Staging of the biopsies was according to Ehrenreich [18]. Biopsies were 
scored quantitatively for the presence of tubulo-interstitial changes. 
in three periods of four weeks, separated by two week 
intervals during which the patients were treated with 125 mg of 
prednisone on alternate days. In case of leucopenia or throm­
bocytopenia the dosage of chlorambucil was reduced. Patients 
were seen at the outpatient clinic at regular intervals. 
Follow-up was at least 24 months in each patient. 
Laboratory parameters were measured using standard techniques. 
A complete remission was defined as a reduction of proteinuria 
to less then 0.2 g/24h, a partial remission as a reduction of 
proteinuria to less then 2.0 g/24h. 
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For statistical analysis we used Student's t-test and Wil-
coxon's test when appropriate. 
RESULTS 
For the whole group of patients the rise in mean serum creati­
nine was interrupted, proteinuria decreased and serum albumin 
increased after start of chlorambucil treatment [Table III]. 
The time course of proteinuria in individual patients is given 
in Fig 1. It is evident that proteinuria decreased in all 
patients after start of chlorambucil and remained below 
baseline values in all patients but one. However, no patient 
reached a complete remission of proteinuria, whereas a partial 
remission at the end of follow-up was noted in only one 
patient. The time course of renal function as reflected by the 
serum creatinine is given in Fig 2. Two patients entered the 
study with normal and stable renal function. In these patients 
no change in renal function was observed. Six patients entered 
the study with evidence of deteriorating renal function. In 
five of them renal function improved or stabilised for several 
months after start of therapy. However, a clear sustained 
improvement of renal function at the end of follow up was 
observed in only two and a stabilization in one. One patient 
progressed to end-stage renal disease within three years after 
start of treatment. 
Table III. Biociiemical parameters before and after chlorambucil treatment. 
Period of observation (months) 
laboratory 
parameters -12 0+ 6 24 
Serum creatinine 136 ± 46* 203 ± 135 176 ± 85 222 ± 126 
[щпоі/і] 
Serum albumin 30 ± 8 28 ± 9 35 ± 7* 35 ± 7* 
[g/i] 
Proteinuria 12.4 ± 4.8 10.3 ± 5.5 4.4 ± 3.3* 6.0 ± 3.6 
[q/24h] 
Values are given eis means ± SD. +; start of dilorairbucil treatment. 
* p<0.05 conpared to values at start of chlorambucil treatment. 
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Proteinuria ( g ^ h ) 
20. 
10. 
-12 12 24 36 
Time (months) 
Figure 1. Time course of proteinuria before and after start of 
chlorambucil treatment at t= 0 months. Patients 
showing an improvement of renal function are depicted 
by an interrupted line. -|-= start of hemodialysis. 
Serumcreatmine (pmol/ l ) 
600-
400· 
200 
-12 12 24 36 
Time (months) 
Figure 2. Time course of serum creatinine before and after 
start of chlorambucil treatment. For explanation see 
figure 1. 
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Side effects of chlorambucil treatment were anorexia and nausea 
[n=3], itching [n=2], and exanthema [n=l]. Furthermore, in five 
patients the dosage of chlorambucil had to be reduced to 0.1 
mg/kg/day and in two the treatment had to be stopped after six 
and eight weeks because of leukocytopenia and/or thrombocyto-
penia. 
DISCUSSION 
Idiopathic membranous glomerulonephritis is characterized by an 
unpredictable course. Although nearly half of untreated pa-
tients will ultimately develop renal insufficiency, still 30-
50% of patients show spontaneous, complete or partial remis-
sions of proteinuria, while renal function remains stable 
[2,3]. Factors associated with a less favourable outcome are 
male sex, older age, nephrotic syndrome, impairment of renal 
function, the presence of tubulo-interstitial changes, his-
tological grade III/IV, and haplotype B18-DR3-BfFl [2,10,Il-
ls ]. Treatment of idiopathic membranous glomerulonephritis is 
controversial [4-6], which can be attributed to the scarcity of 
controlled, prospective trials. Furthermore in most studies, 
prospective as well as retrospective, follow-up of patients is 
rather short, and populations studied are quite heterogeneous. 
In 1979 the results of a well-conducted, prospective controlled 
study were reported, showing beneficial effects of short-term 
treatment with high-dose prednisone on alternate days [7]. 
Although treated patients at the end of follow-up did not have 
more remissions of proteinuria, a decline of renal function was 
prevented. However, these results have not been confirmed in 
more recent trials [8,9], and therefore the beneficial effect 
of prednisone treatment remains questionable. In 1984 favoura-
ble effects were reported of treatment with chlorambucil and 
prednisone [10]. Up to 75% of treated patients reached a 
complete or partial remission of proteinuria, and nearly all 
demonstrated stable renal function. We have studied the effects 
of a similar treatment regimen in patients with persisting 
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nephrotic syndrome and/or deteriorating renal function despite 
treatment with high-dose prednisone. All our patients were men, 
which can be explained by the higher incidence and the less 
favourable outcome of membranous glomerulonephritis in men. The 
treatment regimen resulted in a clearcut decrease of proteinu-
ria parallelled by an increase in serum albumin concentration. 
However, no patient reached a complete remission and in only 
one a sustained partial remission was noted. With respect to 
renal function, the effects of treatment were less evident. 
Overall, no change in serum creatinine was noted. In two 
patients who entered the study with stable and normal renal 
function, this remained unchanged. In six patients who entered 
the study with evidence of deteriorating renal function, a 
sustained improvement was noted in two, and a stabilization in 
one, whereas the other three showed further decline of renal 
function, leading to end stage renal disease in one of them. 
Side effects were frequent, and in all but one patient chloram-
bucil dosage had to be reduced because of leukocytopenia 
and/or thrombocytopenia. 
To our knowledge thusfar only uncontrolled trials have been 
conducted in patients with deteriorating renal function 
[reviewed in chapter II]. The results of these studies indicate 
that renal function can improve in these patients, who, if left 
untreated, relentlessly progress to end stage renal disease. 
Three studies have used combined treatment of prednisone and 
chlorambucil [Table IV] . Excellent results have been obtained 
by Mathieson et al [14], who treated eight patients with 
deteriorating renal function using exactly the Ponticelli 
regime including the initial three pulses of one gram of 
methylprednisolone and chlorambucil in a dose of 0.2 mg/kg/day. 
In all eight patients proteinuria decreased, one reaching a 
complete and three a partial remission. Renal function improved 
in six, and stabilised in one. Although in their original 
article follow-up was rather short, averaging 11 months, the 
improvement was sustained after a mean follow up of 18 months 
[15]. In the study of Warwick and Boulton-Jones [16], seven pa-
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Table IV. Sunmary of therapeutic trials using chlorambucil in patients with 
menbranous glanerulonephritis and deteriorating renal function. 
Ref. Patients Sex Creatinine Follow-up Proteinuria Renal function 
(no) Ц/Б" (/япоі/і) (months) CR ER IM S ESRD 
14 8 7/1 194 18 1 3 6 1 1 
[122-312] 
16 7 7/0 300 11 1 1 1 3 0 
[180-480] 
I h i s 6 6/0 235 33 0 1 2 1 1 
Study [126-511] 
Abbreviations: CR=ocniplete remission, H ^ a r t i a l remission, IM=iiiprOved, 
S=stabi l ised, ESRD=end stage renal d isease. 
tients were treated with monthly cycles of prednisone and 
chlorambucil. These authors, like we, did not use pulses of 
methylprednisolone, and used a lower dose of chlorambucil [0.12 
mg/kg/day]. They noted an improvement of renal function in one 
patient and stabilization of renal function in three others. 
The results of the latter study are very similar to ours, and 
clearly less impressive than the results of Mathieson et al. 
What has caused these differences? In view of the small numbers 
of patients it might have occurred by chance. Alternatively, 
patient groups are somewhat different, renal function being 
more severely impaired in the patients of Warwick and Boulton-
Jones, whereas our patients all had been unsuccesfully treated 
with prednisone. Lastly, differences in treatment regimens 
might be important. Although the recommended dosage schedule 
was different in the three studies, the average chlorambucil 
intake was quite similar, mainly because the development of 
leukocytopenia and thrombocytopenia necessitated dose reduction 
in our and Mathieson's study. The main difference in the 
treatment schedules was the use of intravenous pulses of 
methylprednisolone by Mathieson and colleagues. Although no 
firm evidence exists about the superiority of pulses methyl­
prednisolone in the treatment of primary glomerulonephritis, 
the omission of these pulses in our and Warwick's study might 
explain the different results. In this regard it is interesting 
that Short and colleagues, who used pulses methylprednisolone 
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in addition to high dose oral prednisone were able to reverse 
the progression of renal failure in nine of 15 patients with 
deteriorating renal function [17]. 
Up to this moment no definite conclusions can be drawn from the 
studies mentioned. However, it is evident that patients with 
membranous glomerulonephritis and deteriorating renal function 
may respond to several different immunosuppressive regimens. If 
the results of the study of Mathieson et al. are confirmed in 
further trials it would allow us to limit immunosuppressive 
therapy to patients with progressive disease. In patients in 
whom the disease will follow an indolent course without 
progression to renal failure unnecessary treatment with its 
associated short-term adverse effects and its potential long-
term hazards could be avoided. 
APPENDIX 
The following colleagues participated in the Study Group: Dr. 
R. Go, Nijmegen, Dr. G. Jordans, Enschede, Dr. R. v.Leusen, 
Arnhem, Dr. R. Schlattmann, Roosendaal, Dr. V. Verstappen, 
Venlo, and Dr. A. Woittiez, Almelo. 
114 
REFERENCES 
1. Coggins CH. Membranous nephropathy. In: Schrier RW and 
Gottschalk CW, ed; Diseases of the Kidney, Little,Brown, 
and Company, Boston 1988,p. 2005-2033. 
2. Davison AM, Cameron JS, Kerr DNS, Ogg CS, Wilkinson RW. The 
natural history of renal function in untreated idiopathic 
membranous glomerulonephritis. Clin Nephrol 1984; 22: 61-
67. 
3. Donadío JV, Torres VE, Velosa JA, Wagoner RD, Holley KE, 
Okamura M, Ilstrup DM, Chu СР. Idiopathic membranous 
nephropathy: the natural history of untreated patients. 
Kidney Int 1988; 33: 708-715. 
4. Cameron JS. Membranous nephropathy: the treatment dilemma. 
Am J Kidney Dis 1982;1: 371-375. 
5. Glassock RJ. Corticosteroid therapy is beneficial in adults 
with idiopathic membranous glomerulopathy. Am J Kidney Dis 
1982; 1: 376-385. 
6. D'Achiardi-Rey R, Pollak VE. Membranous glomerulonephropa-
thy: there is no significant effect of treatment with 
corticosteroids. Am J Kidney Dis 1982; 1: 386-391. 
7. Collaborative study of the Adult Idiopathic Nephrotic 
Syndrome. A controlled study of short-term prednisone 
treatment in adults with membranous nephropathy. New Engl J 
Med 1979; 301: 1301-1306. 
8. Cameron JS. The MRC trial of prednisolone in membranous 
nephropathy. Nephrol Dial Transplant 1988; 3: 844 [ab­
stract] . 
9. Cattran DC, Delmore T, Roscoe J, Cole E, Cardella С, 
Charron R, Ritchie S, Toronto glomerulonephritis study 
group. A randomized controlled trial of prednisone in 
patients with idiopathic membranous nephropathy. New Engl J 
Med 1989; 320: 210-215. 
10. Ponticelli С, Zuchelli Ρ, Passerini Ρ, Gagnoli L, Cesana В, 
Pozzi С, Pasquali S, Imbasciati E, Grassi С, Redaelli В, 
Sasdelli M, Locateli! F. A randomized trial of methylpred-
nisolone and chlorambucil in idiopathic membranous nephro­
pathy. New Engl J Med 1989; 320: 8-13. 
11. Hopper J, Trew PA, Biava С. Membranous nephropathy: its 
relative benignity in women. Nephron 1981; 29: 18-24. 
12. Short CD, Dyer PA, Cairns SA, et al. A major histocompati­
bility system haplotype associated with poor prognosis in 
idiopathic membranous nephropathy. Disease Markers 1983; 1: 
189-196. 
13. Ponticelli С, Zuchelli Ρ, Imbasciati E, Gagnoli L, Pozzi С, 
Passerini Ρ, Grassi С, Limido D, Pasquali S, Volpini Τ, 
Sasdelli M, Locateli! F. Controlled trial of methylpred-
nisolone and chlorambucil in idiopathic membranous nephro­
pathy. New Engl J Med 1984; 310: 946-950. 
14. Mathieson PW, Turner AN, Maidment CGH, Evans DJ, Rees AJ. 
Prednisolone and chlorambucil treatment in idiopathic 
membranous nephropathy with deteriorating renal function. 
Lancet 1988;II: 869-872. 
115 
15. Mathieson PW, Maidment CGH, Rees AJ. Immunosuppression for 
membranous nephropathy. Lancet 1989; I: 212. 
16. Warwick G, Boulton-Jones JM. Immunosuppression for membra-
nous nephropathy. Lancet 1988;II: 1361. 
17. Short CD, Solomon LR, Gokal R, Mallick NP. Methylpredniso-
lone in patients with membranous nephropathy and declining 
renal function. Q J Med 1987; 65: 929-940. 
18. Ehrenreich J, Churg J. Pathology of membranous glomerulo-
nephritis. Pathol Ann 1986; 3: 145-149. 
116 
SUMMARY AND DISCUSSION 

In 1979, beneficial effects of prednisone treatment were 
reported in patients with membranous glomerulonephritis [1]. 
The authors advised to use an alternate day regimen, in order 
to reduce side effects. While treating patients with membranous 
glomerulonephritis according to this regime, we noted an 
increase of proteinuria on prednisone days [2]. These observa-
tions prompted further studies on this effect. The results of 
these studies form the main theme of this thesis. When studying 
the effects of prednisone on proteinuria some methodological 
questions arose, such as the influence of urine flow on 
proteinuria, the reliability of creatinine as a marker of 
glomerular filtration, and the possibility to measure the 
influence of the charge of the glomerular basement membrane on 
proteinuria. These questions were addressed in separate 
studies. Finally, because recent studies have questioned the 
efficacy of prednisone treatment in patients with membranous 
glomerulonephritis, we have analysed the course of the disease 
in our patients, who were treated with prednisone alone, or in 
combination with chlorambucil. 
Methodological studies 
Under normal living conditions both normal and pathologically 
increased urinary protein excretion rates are quite variable, 
and dependent on posture, exercise, diet, time of the day, and 
preciseness of urine sampling. In a clinical setting most of 
these factors can be controlled. Uncertainty existed on the 
influence of urinary flow rate on proteinuria. We have there-
fore studied the relation of protein excretion to urinary flow 
rate in patients with renal disease and proteinuria. At a 
urinary flow rate above 1.5 ml/min proteinuria is fairly 
constant and independent of diuresis. However, at flow rates 
below 1.0 ml/min proteinuria is diminished, which might result 
from an increased tubular protein reabsorption. During hemody-
namic studies performed over a short period of time, it is not 
difficult to keep diuresis constant over 2.0 ml/min. However, 
when urine is sampled over longer periods e.g. 24 hours, 
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diuresis will hardly ever exceed 1.5 ml/min, i.e. 2.2 L/day. 
Therefore, it is important that urinary flow rate is accounted 
for when measuring proteinuria. 
In recent years evidence has been gathered mostly from animal 
experiments showing that protein transport is determined not 
only by the size of the molecules involved but also by their 
charge. Information on the charge selective properties of the 
glomerular filter cannot easily be obtained in humans. It is 
well known that in normal serum two major amylase isomers 
exist, pancreatic-amylase [P-amylase] and salivary-amylase [S-
amylase]. These iso-enzymes have an identical size [2.9 nm], 
but different charge, S-amylase [iso-electric point 5.9-6.4] 
being more anionic than P-amylase [iso-electric point 7.0]. We 
have investigated whether this difference could be used to 
obtain insight into the charge selective properties of the 
glomerular basement membrane in the clinical situation. In a 
pilot study we studied the clearances of these amylase iso-
enzymes in healthy subjects and in patients with renal disease 
and variable proteinuria. In agreement with our understanding 
of the charge selective properties of the glomerular basement 
membrane we observed that in the healthy subjects renal 
clearance of neutral P-amylase exceeded the clearance of the 
anionic S-amylase. In patients with renal diseases clearance of 
S-amylase was relatively increased, consistent with a defect in 
the charge-selectivity properties of the glomerular capillary 
wall. Comparing patients with normal and abnormal tubular 
function no difference in the ratio of the fractional clearan-
ces of P-amylase and S-amylase was observed, which indicates 
that both iso-enzymes are processed by the tubules in the same 
way. Although these results suggest that it is worthwile to 
study further the possible usefulness of measuring the frac-
tional clearances of P- and S-amylase as markers of glomerular 
basement membrane charge, some restrictions should be made. 
First, the inhibitor technique that we have used for measuring 
amylase iso-enzymes is rather insensitive, especially if the 
proportion of P-amylase in the urine exceeds 90%. In fact, as 
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mentioned, we could not determine urinary S-amylase in 11 of 
63 subjects. Secondly, we cannot exclude that the inhibition 
characteristics of the inhibitor are influenced by uremic 
products in the patients' serum or urine. To circumvent these 
problems, we are currently investigating a technique using 
monoclonal antibodies that specifically inhibit s-amylase. 
Results thusfar are promising [3]. Further studies are planned 
to determine if we can find changes in the excretion patterns 
of S-amylase in diabetic patients, in whom glomerular basement 
membrane charge decreases at an early stage of the disease. 
Thusfar we have studied patients with microalbuminuria, and 
found no major differences in the excretion patterns of S- and 
P-amylase. This is somewhat disappointing, and might indicate 
that the method is not sensitive enough to detect minor changes 
in glomerular basement membrane charge. 
The glomerular filtration rate [GFR] is an important parameter 
of renal function. In routine clinical practice creatinine is 
widely used as a marker of GFR. In recent years, the reciprocal 
of serum creatinine [1/Screat] has become popular for examining 
changes in renal function in time and for assessing the 
possible effects of therapeutic interventions. However, there 
are several pitfalls in the use of creatinine as marker of GFR. 
It is important to realise that serum creatinine and urinary 
creatinine excretion are partially dependent on creatinine 
derived from exogenous sources, especially meat. Furthermore, 
tubular secretion and metabolism may contribute substantially 
to creatinine disposal. The variability of these factors makes 
creatinine an unreliable marker of GFR, especially in clinical 
studies where relatively small changes in renal function have 
to be detected. A striking example of the problems that can 
arise when using 1/Screat to follow renal function in time 
comes from studies on the effects of protein restriction on the 
progression of renal failure. These studies have claimed that 
early protein restriction can retard the rate of progression of 
renal insufficiency, and indeed investigators have observed a 
rise in 1/Screat after protein restriction suggesting an 
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amelioration of renal function. However, a reduction of dietary 
meat intake will lead to a gradual decrease of serum creatinine 
and a parallel reduction in urinary creatinine excretion. Based 
on these data, one would expect that reduction of meat intake 
per se causes an increased 1/Screat, independent of changes in 
renal function. Indeed, it has been demonstrated that in such 
cases 1/Screat suggested an improvement of renal function, 
whereas the measured creatinine clearance actually decreased. 
Furthermore, we could demonstrate that dietary protein intake 
influences creatinine secretion. When we prescribed a high 
protein diet for four weeks to patients with renal failure, we 
observed that creatinine secretion increased. More recently we 
have studied the influence of a meat meal on the tubular 
secretion of creatinine in healthy subjects [4]. Our results 
indicated that the meat meal almost doubled creatinine secre-
tion. Thus, in clinical studies creatinine cannot not be used 
as a precise marker of GFR. 
Prednisone-induced alterations in proteinuria 
Glucocorticoid treatment is regularly used in patients with a 
nephrotic syndrome. While treating patients with a nephrotic 
syndrome with corticosteroids in an alternate-day regime, we 
observed a typical fluctuating pattern of proteinuria, protein 
excretion on prednisone days exceeding that on non-prednisone 
days [2]. The percentual change of proteinuria correlated with 
baseline endogenous creatinine clearance. In view of evidence 
in the literature, the alterations in proteinuria during 
alternate day prednisone therapy were initially attributed to a 
prednisone-induced increase of protein excretion. To unravel 
the mechanisms of this effect we have studied patients with 
either membranous glomerulonephritis or minimal change disease 
and a nephrotic syndrome more closely. The acute proteinuric 
effects of prednisolone were studied in nine patients. After 
intravenous administration of 125-150 mg of prednisolone, 
urinary protein excretion rose in all patients, percentual 
increases ranging from 21% to 178% [median 95%]. Glomerular 
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filtration rate and effective renal plasma flow did not change 
significantly. The percentual increases of urinary excretion of 
albumin, IgG, and transferrin were in the same range. Urinary 
excretion of /32-microglobulin did not change significantly, 
however. These observations suggest that the increase of 
urinary protein excretion after administration of prednisolone 
cannot be explained by changes in renal hemodynamics or tubular 
protein reabsorption, and might be the result of a change in 
glomerular permselectivity characteristics. 
Retrospective analysis of our data suggested that the differen-
ces in protein excretion on prednisone and non-prednisone days 
could also at least partly be the result of a decreased 
proteinuria on non-prednisone days. The magnitude and the 
possible mechanisms of the decreased protein excretion on non-
prednisone days were studied in more detail in 14 patients with 
a nephrotic syndrome and membranous glomerulonephritis. In 
these patients renal hemodynamics and proteinuria were studied 
at base-line and six days after starting alternate day pred-
nisone treatment on a non-prednisone day. Proteinuria decreased 
from 7.7 ± 1.9 to 4.9 ± 1.5 mg/min [percentual decrease 45±8%; 
p<0.01]. Glomerular filtration rate and renal plasma flow did 
not change significantly. However, filtration fraction decrea-
sed slightly, but significantly, by 7 ± 2%. Percentual decrea-
ses of albumin, IgG, and transferrin excretion were comparable, 
whereas excretion of /?2-microglobulin was less reduced. From 
these observations we conclude that proteinuria is decreased on 
a non-prednisone day. This decrease of proteinuria is mediated 
by a decreased glomerular capillary pressure and a change in 
glomerular size-selectivity. 
On the non-prednisone day endogenous Cortisol production was 
depressed, plasma Cortisol decreasing from 0.27 ± 0.04 mmol/1 
at base-line to 0.10 ±0.02 mmol/1 [p<0.01]. Could this change 
in Cortisol levels be related to the alterations in proteinu-
ria? Adrenalectomy reduces proteinuria in rats. Substitution 
therapy with glucocorticoids but not mineralo-corticoids 
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restores proteinuria. From these observations it was concluded 
that glucocorticoids have a permissive effect on proteinuria. 
The effects of glucocorticoids on proteinuria may be the result 
of a change in glomerular filtration rate as well as a direct 
effect on glomerular permeability. The results of our studies 
suggest that glucocorticoids, in casu prednisone, also inter-
fere with proteinuria in humans. Recent studies have stimulated 
the interest in the effects of steroids on proteinuria. First, 
in the remnant kidney model in the rat, a non-inununological 
model of progressive renal failure, chronic administration of 
pharmacological doses of methylprednisolone accelerated the 
development of glomerular sclerosis. Secondly, in human 
individuals with renal failure a positive correlation was found 
between the rate of progression of renal insufficiency and the 
excretion of 17-hydroxysteroids. These data suggest that 
corticosteroids, even when levels are within the physiological 
range, may play a role in the deterioration of renal function. 
If this is the case, even low doses of prednisone, administered 
daily, could contribute to the progression of renal failure. 
The results of our studies could have, therefore, important 
clinical consequences. Alternate day prednisone therapy may be 
less detrimental and also new therapeutic approaches using 
antiglucocorticoid drugs may be worthwile to explore. Clearly, 
more studies on the effects of prednisone in patients with 
renal disease are needed to substantiate these speculations. 
Clinical and therapeutic aspects. 
Membranous glomerulonephritis is the most common glomerular 
disorder underlying the nephrotic syndrome in adults. The 
natural history of the disease in untreated patients is quite 
variable. A rough estimate learns that half of the patients 
will reach remission of proteinuria, whereas the other half 
will develop renal insufficiency. Up to this time no definitive 
answer can be given to the question how to treat these pa-
tients. Two controlled trials using prednisone monotherapy have 
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yielded equivocal results. Therefore we analysed the course of 
the disease in 34 patients, who had been treated with 125 to 
150 mg of prednisone on alternate days. Female patients [n=6] 
had a good prognosis, none of them progressing to renal 
failure. However, more than half of the men developed renal 
insufficiency, and only three reached a complete remission of 
proteinuria within one year after starting the treatment. It is 
not justified to draw firm conclusions from such an uncontrol-
led study. However, it is evident that the majority of patients 
will not benefit from steroid treatment. Recently the results 
of a controlled trial have been reported, demonstrating 
beneficial effects of combined treatment with chlorambucil and 
prednisone in patients with membranous glomerulonephritis and 
well preserved renal function. Nearly three quarter of patients 
reached a complete or partial remission of proteinuria, and 
only a few developed renal insufficiency. It is evident that 
these results are superior to those obtained by treatment with 
prednisone alone. Should we then offer all our patients this 
treatment regimen? One must be careful to jump to conclusions 
in this difficult field. First, the results have to be con-
firmed in other controlled trials. Secondly, membranous 
glomerulonephritis is a disease with a rather indolent course, 
and over 50% of the patients will spontaneously improve. If we 
treat all patients, the latter group will unnecessarily be 
exposed to the short-term adverse effects and the potential 
long-term hazards of chlorambucil treatment. Ideally, such 
aggressive treatment regimens should be restricted to patients 
with a high likelihood of developing renal insufficiency. As 
mentioned above, such patients can be identified within two to 
three years after presentation. Can the start of treatment be 
delayed safely until renal function starts to deteriorate? 
Recent uncontrolled studies have furnished important informa-
tion on this subject. Patients with membranous glomerulonephri-
tis and deteriorating renal function are not invariably resis-
tant to treatment. In fact, in 50 to 70% of patients renal 
function improved or stabilised after treatment with regimes 
including cyclophosphamide, azathioprine, chlorambucil, or 
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prednisone. We have used combined treatment of chlorambucil and 
prednisone in six patients with renal insufficiency, and noted 
an improvement or stabilisation of renal function in three of 
them. Further studies in such patients are needed to confirm 
the effectiveness of treatment regimens and to select the best 
possible drug or combination of drugs. 
Concluding remarks 
Our experience with prednisone monotherapy in patients with 
membranous glomerulonephritis is somewhat disappointing. 
Although serious side effects rarely occur, the benefits of 
treatment are doubtful, so that we cannot longer recommend to 
treat all patients with idiopathic membranous glomerulonephri-
tis with an eight week course of prednisone. Up to this moment 
the question remains open, if addition of pulses methylpred-
nisolone could enhance the therapeutic efficacy of prednisone 
monotherapy. Newer treatment regimes including combined 
treatment with chlorambucil and prednisone are clearly more 
effective, even in patients with established renal failure. We 
feel that it is important to restrict such treatment regimes to 
patients with a high likelihood of developing renal insuffi-
ciency. Patients without [a high risk for] renal insufficiency 
should not be treated with such aggressive drugs. It seems 
worthwile to explore prospectively the effectiveness of pulses 
methylprednisolone in the latter group of patients. 
Although the therapeutic effects of prednisone monotherapy did 
not meet our expectations, the use of it has drawn our atten-
tion to rather unexpected acute effects of prednisone on 
proteinuria. In our view the decrease of proteinuria on non-
prednisone days could have important clinical consequences. Our 
data fit well with the idea that a decreased production of 
Cortisol could attenuate protein excretion and retard progres-
sion of renal insufficiency. The introduction of antiglucocor-
ticoid drugs, which specifically antagonise the effects of 
glucocorticoids at the receptor level, will make it possible to 
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study further the effects of Cortisol on proteinuria. It will 
be interesting to see whether these antiglucocorticoid drugs 
can decrease proteinuria. If this is the case, these drugs 
might be useful for therapeutic intervention. The fact that 
proteinuria is intermittently decreased during alternate-day 
prednisone therapy might indicate that such a regime is 
preferable to daily prednisone treatment. In this regard it 
would also be interesting to study renal transplant recipients 
with proteinuria and chronic vascular rejection. These patients 
use prednisone on a daily basis. It is conceivable that 
alternate day treatment might retard the progression of renal 
failure in these patients. 
The relevance of our finding of an acute proteinuric effect of 
prednisone is less clear. The increased proteinuria may simply 
reflect the damaging potential of prednisone on the glomerular 
filter. However, in recent studies in patients with prolifera­
tive glomerulonephritis we could not detect such an increase of 
protein excretion after administration of prednisone. This 
might indicate that the nature of the underlying disease and 
possibly the nature of the defect in the glomerular basement 
membrane determines the response to prednisone. These findings 
call for further studies of the effects of prednisone in 
patients with renal failure. 
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SAMENVATTING 

Membraneuze glomerulonefritis is de meest frequente oorzaak van 
het nef rotisch syndroom bij volwassenen. In 1979 werd een 
behandelingsschema geïntroduceerd bestaande uit 125 tot 150 mg 
Prednison op alternerende dagen gedurende acht weken. Bij de 
behandeling van patiënten volgens dit schema viel op dat de 
eiwituitscheiding op prednison-dagen duidelijk hoger was dan op 
de dagen dat de patiënten geen prednison gebruikten. Deze 
klinische waarneming leidde tot nader onderzoek, waarvan de 
resultaten in dit proefschrift zijn weergegeven. 
Het natuurlijk beloop van de membraneuze glomerulonefritis is 
wisselend fhoofdstuk 111 · Globaal genomen komt de helft van de 
patiënten spontaan in remissie, terwijl de andere helft een 
nierinsufficientie ontwikkelt. Voor vrouwen is de prognose 
gunstiger. Het nut van behandeling met prednison alleen is 
omstreden; nieuwere behandelingsschema's met cyclophosphamide, 
chloorambucil of azathioprine lijken effectiever en ook werk-
zaam bij patiënten met een reeds bestaande nierinsufficientie. 
Wij onderzochten de invloed van de urine flow op de eiwituit-
scheiding bij patiënten met evidente Proteinurie [hoofdstuk 
III]. De eiwituitscheiding is bij een diurèse van meer dan 1,5 
ml/min [=2,2 L/24 uur] constant en onafhankelijk van de 
urineproductie. Bij lagere diurèse neemt de eiwituitscheiding 
af, mogelijk door een toegenomen tubulaire reabsorptie. Bij 
onderzoek naar veranderingen in de eiwituitscheiding moet dan 
ook gestreefd worden naar een diurèse van meer dan 1,5 tot 2,0 
ml/min. 
De doorlaatbaarheid van de glomerulaire basale membraan [GBM] 
wordt ten dele bepaald door de negatieve lading ervan. Een 
afname van de negatieve lading kan leiden tot fors eiwitver-
lies, met name door toegenomen lekkage van albumine. Wij 
onderzochten of de verhouding van de klaring van het neutrale 
pancreas-amylase [P-amylase] en het negatief geladen speek-
selklier-amylase [S-amylase] een maat zou kunnen zijn voor de 
negatieve lading van de GBM [hoofdstuk IV] . Bij proefpersonen 
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bleek inderdaad de klaring van P-amylase hoger dan de klaring 
van S-amylase. Bij patiënten met een nierziekte en Proteinurie 
bleek de klaring van S-amylase relatief toegenomen, hetgeen in 
overeenstemming is met het bekende verlies van lading van de 
GBM bij deze patiënten. Het is echter de vraag of de bepaling 
van de klaringen van P- en S-amylase voldoende gevoelig is om 
kleine veranderingen in de negatieve lading aan te tonen. 
In hoofdstuk V worden verschillende factoren besproken die de 
waarde van serumcreatinine en de creatinineklaring als maat 
voor de nierfunctie beperken. Het belangrijkst in dit verband 
zijn de sterke variabiliteit in de tubulaire secretie en het 
extrarenale metabolisme van creatinine. Ook het feit dat de 
voeding, in casu vlees, een belangrijke bron van creatinine is, 
bemoeilijkt in vele gevallen de interpretatie van nierfunctie-
gegevens op basis van creatininebepalingen. 
Hoofdstuk VI geeft een overzicht van de waarnemingen tijdens de 
behandeling van patiënten met een nefrotisch syndroom met hoge 
dosis prednison op alternerende dagen. Op prednison-dagen bleek 
de eiwituitscheiding anderhalf tot twee maal zo groot als op 
niet-prednison-dagen. De mate van verschil was gecorreleerd met 
de creatinineklaring. Bij patiënten die niet met diuretica 
behandeld werden leek de eiwituitscheiding, met name op de 
eerste dag van de behandeling, extra toe te nemen. In een 
vervolgonderzoek bleek dat intraveneuze toediening van Pred-
nisolon binnen vijf uur leidde tot een sterke toename van de 
Proteinurie met gemiddeld 95% [hoofdstuk VII]. De toename van 
de Proteinurie ging niet gepaard met veranderingen in de 
nierfunctie noch in de uitscheiding van /?2-microglobuline. Dit 
maakt het aannemelijk dat de toename van de Proteinurie berust 
op een verandering in de glomerulaire permeabiliteit. 
In hoofdstuk VIII wordt duidelijk aangetoond dat de beschreven 
wisselingen van de eiwituitscheiding tijdens prednisonbehande-
ling voor een belangrijk deel berusten op een afname van de 
Proteinurie op niet-prednison-dagen. De afname van de proteinu-
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rie gaat gepaard met een verminderde filtratiefractie. Er 
worden vergelijkbare veranderingen in de uitscheiding van 
albumine, IgG, en transferrine gevonden. Deze gegevens duiden 
erop dat de afname van de eiwituitscheiding berust op een 
verminderde intraglomulaire druk en een verminderde permeabili-
teit van de GBM. Een en ander wordt mogelijk veroorzaakt door 
de waargenomen suppressie van de endogene cortisolproductie op 
de niet-prednison-dagen. Recente studies bij patiënten met een 
nierinsufficientie wijzen op een verband tussen de endogene 
glucocorticoidproductie en de snelheid van nierfunctieverlies. 
Ondanks behandeling met hoge dosis prednison gedurende acht 
weken ontwikkelde meer dan de helft van de mannelijke patiënten 
met een membraneuze glomerulonefritis een nierinsufficientie 
fhoofdstuk 1X1 . Daarentegen ontwikkelde geen van de zes aldus 
behandelde vrouwen een nierinsufficientie. Gaat de nierfunctie 
achteruit, dan gebeurt dit meestal binnen twee tot drie jaar na 
het begin van de ziekte. Patienten die een nierinsufficientie 
ontwikkelen worden gekenmerkt door hoge bloeddruk, ernstige, 
niet-selectieve Proteinurie en een verhoogde uitscheiding van 
/32-microglobuline. Hoewel het een niet-gecontroleerde studie 
betreft, lijkt de effectiviteit van prednisonbehandeling op 
deze wijze niet groot. Naar aanleiding van beschreven gunstige 
effecten van behandeling met de combinatie chloorambucil en 
prednison bij patiënten met een membraneuze glomerulonefritis, 
behandelden wij een aantal patiënten met een dergelijke 
combinatie van middelen [hoofdstuk X] . Alle patiënten hadden 
een persisterend nefrotisch syndroom en/of een nierinsufficien-
tie ondanks behandeling met prednison alleen. Wij zagen slechts 
bij één patient een partiele remissie van de Proteinurie. 
Echter, van de zes patiënten met tevoren een dalende nier-
functie, verbeterde deze bij twee, en bleef stabiel bij een 
derde patient. Op dit moment lijkt het daarom het verstandigst 
deze behandeling te reserveren voor patiënten die reeds ach-
teruitgang van de nierfunctie tonen. 
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STELLINGEN 
I 
De bevinding dat suppressie van de endogene cortisolproductie 
gepaard gaat met een sterke afname van de Proteinurie opent 
therapeutische perspectieven voor patiënten met een nefrotisch 
syndroom. 
II 
Behandeling van patiënten met een membraneuze glomerulonefritis 
met hoge doses prednison gedurende acht weken is onvoldoende 
effectief. 
III 
De achteruitgang van nierfunctie bij patiënten met een 
membraneuze glomerulonefritis is niet onherroepelijk. 
IV 
Bij patiënten die na niertransplantatie recidiverend tekenen 
van onverklaarde overhydratie of decompensatio cordis vertonen, 
dient een sténose van de nierarterie uitgesloten te worden. 
V 
Het beloop van de diabetische nephropathie na niertrans-
plantatie is niet natuurlijk. 
VI 
Patienten met diabetes mellitus hebben na een geslaagde nier-
transplantatie waarschijnlijk een verhoogde kans op het 
ontstaan of het verergeren van perifere circulatie-stoornissen, 
waarvoor amputaties noodzakelijk zijn. 
VII 
Intraveneuze toediening van vincristine kan leiden tot spasme 
van de coronairarterien en tot myocardinfarct. 
Vili 
De toename van de lithiumklaring na toediening van triamtereen 
maakt de aanwezigheid van lithiumtransport in de corticale 
verzamelbuis aannemelijk. 
IX 
Het is vooralsnog niet afdoende bewezen dat vroegtijdige, 
strenge eiwitbeperking bij patiënten roet een nierinsufficientie 
het voortgaande verlies van nierfunctie vertraagt. 
X 
Gelet op de belangrijke bijdrage van exogeen creatinine is de 
benaming ECC [ endogenous creatinine clearance ] misplaatst. 
XI 
De term "reserve-capaciteit van de nier" dient afgeschaft te 
worden. 
XII 
Toediening van anti-thymocytenglobuline [ATG] vormt een ef-
fectieve therapie van afstotingsreacties bij niertrans-
plantatiepatienten die met cyclosporine behandeld worden. 
XIII 
Een toegenomen oxidatief metabolisme in de tubuluscellen speelt 
waarschijnlijk een belangrijke rol bij de meestal onafwendbare 
progressie van chronische nierinsufficientie. 
XIV 
Ook uit wetenschappelijk oogpunt is het schrijven van een 
proefschrift niet de meest nuttige vrije-tijdsbesteding. 
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